R¢gist*rnd number: 0823￿97 Charity number: 1149638 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Llmlted by Guarantee) TRUSTEES. REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 Iillwillll *AC81N5KX* #178 COMPANIES HOUSE THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Conwny Limtsd by Guarantee) CONTENTS Page Refe￿￿e and Administrati￿ D•tails of the Company. its Trust•e5 and Advisers Truste•s' Rtport 2-16 Trustees. Respon$ibllttl•s Statèmtnt Independent Auditors. Report on the Finanelal Statements 18-21 Statement of Fin•n¢i41 ktivi¢ies 22 Balance Sheet 23 Statefflent of Cash Flows 24 Notes to the Flnan¢l•l Statements 25-44 THE FEOERATION OF EUROPEAN BIOCHEMICAL SOCIETIES Company Linatsd by Guarant*l REFERENCE ANO ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND AOVISERS FOR THE YEAR ENDEO 31 DECEMBER 3J22 Trusttts V Paèes, secret￿ Genèral {appoinled 1 January 2017, t&mi èndèd 31 December 20221 P Laidkr. Chaii Ex•cutNe Corrwnittee lappointed 1 January 2020) F Michelangeli, T￿¥Surer lappointed 1 January 20171 F G Salin, Chair, Education Commrttee lapwnted l Januwy 20191 l Diaz Moreno, Chair. W0￿"ng Group on thè Carèèrs of Young Scientists (appointed 1 January 20181 C Arraiano. Chair. Working Group on Women in Science {appointed 1 January 2014, tÈrm ended 31 December 20221 B Vértessy, Chair, AdvancerKlge. C82 3BZ Company secretary Professor M Dè La Rtssa Independent audStors Hitl W¢)oidndge & Co. ￿M￿tI. 107 Hindes Rtsad, HarTOW. Middlesex. HA1 1RU B￿kerS HSBC UK 8ank PLC. 1st FlrvJr. SuMin9dak. The Bety Business Part Colonial Way, Watrord. WD24 4WH In￿￿tMent managers J.P. Morgan Pnvate Bank, 60 Vidoria Embankmtnt, London. EC4Y WP Page 1 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarantee) TRUSTEes' REPORT FOR THE YEAR ENOEO 31 DECEMBER 2022 The Trustees present their annual report logelher wth the audrted ffinancial statement5 Qf thg Corrpany for the year 1 January 20r2 to 31 Dtetrrkner 2022. The Annual Report SèNèS the purposès of both a TrustèÈs' report and a directors. report under company law. The Trustees confirm that the Annual Report and financial statements of the charrtat4e Company compty with the currenl statutory requirernents, the requirements of the charitable companys goveming document and the provisKJns of tht Statèment of Recommended Practi¢e ISORPI applKable to charrt'es prepanng their accounts In accordance wrth the Financial Reporting Standard appluble in the UK and Republic of Ireland {FRs1￿2) lelfectNe 1 January 20191. Sine8 th& Company qualth as uThJer sectK)n 382 of the Coryanps Act 20C6, thg *ratogi¢ Rgport requiréd of mèdium and large companies uTrJer th• Cornpanie5 Ad 20C6 (Strategic R•port and Directors. Report) Regulabons 2013 has been omrtted. STRUCTURE. GOVERNANCE AND MANAGEMENT Con$titution FEBS is reglstered as a charty lie9tstered chawty number 114>338}. and is a company limrted by guarantee Iregi51ered company number 08239)971. The Memorandum and Artic￿$ of Assoc¢atson by which FE8S was governed in 2022 can be found here.. ht￿S.'1￿￿￿.rebs.¢rfftC0ntenUuplQadsl2022lo8ffEBS_- Mernofandum and Articles of_ASsociat￿n.pdf. Organisation and membership FEBS was founded on 1st January 1964 and is a Federab"on of biochemisty and molecular b¢ology Societ￿5. In 2022, its Constrtuent socieb.es spanned 39 countrie5 in Europe and neghbouring regions and included 35 Member So¢ielEs and 4 Associate Ilember Soc*ties. The Constrtuent Soc*kn"es of the Federation in 2022 are 9iven in Appenth'x l. and theif ry*mb•rSh￿ nurnbers fft AP￿ndiX 2 It¢)laling 25.836 indwidual members in 20221. 12 societies - Russia and Belarus - had their menknrship of FEBS suspended follomny a Counul vote in 2022 and they currently remain suspended.) FEBS is govemed by a Council composed of one de￿gate from each of the Con5b"luenl Societies as well as the member5 01 the ExeoJtwe Committee. FEBS Council meets once a year al the annual FEBS Congress. Th¢ Council elects members ol the FEBS ExèculNe Commrttee for three-year term5 (except the Chair and Vice- Ch¥ir posr(ionsl. as well as ordinary mèmbets ofthe FE8S Commrttees and Working Group5 (delegated specific areas of FEBS wofkl for four-￿ar terms, in a secret ballot. The v￿-ChaIr of the Execulwe Committee, who after one year becomes Chair. is app)inted by the Swety hostsng the annual Congress and Council Meetsng in the wevious year. Subject to the Couneil, the adThMnislrabon tsf the Ftderation is vested in the FEBS ExecutNe Committee (the 'FE8S Offi"cers'l. The Exe¢ub"ve Commrttee consists of the Chairperson. the Vice£hairpèrson, the FEBS Sec￿tary General. the FEBS Tièasurer, the FE8S Congress Counselh)r, and the FEBS Committee and Wo¥king Cioup Chairp8r50ns. Wrth the eXcept￿n ol co-OPte(J ActiThJ Chairpetsons le.g. following resignations pr￿r to Council eleciK)nsl, FEBS Olficer5 are the FEBS ¢hanty Trustees and company DireLttors respon$ible for the actions ol FEBS. The narnes of the membèrs of the Execukn"vè Comrruttee and the narnes of members ol other Committeès and WoTking Groups in 2022. together with dates of app(Mntrnents and 9eographKal distribution, are set out in Appendix 3. The FEBS Trusteesnirectors are distingurshed srAentsts and Iwth the exception ol the Executwe Committee Vicè Chair and Chair. as explained above) elected by FEBS Counul from norninations put forward by FEBS Constrtuent Sociètiès. Before formal appM)intment, nth￿Y elected TrUsteeS￿lreCtors sign the Chanty Commission's 'Declaration of eligibilty for ￿ appointed Trustees, and are referred to the Charity Commisslon's gU￿ance ￿ the ro￿ of Trustse$ a$ well as Companies House Inlormath?n on Directorlsecretary r&es Page 2 TIIE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarantttl TRUSTEES. REPORT ICONTINUEDI FOR THE YEAR ENDEO 31 DECEMBER 2022 OWECTIVES ANO ACTlVtnES Oblectlvés The obieetwes of FEBS are to ¢ontribule to and promote the èdwdn¢ement of rese8r¢h and edueth.oft for the public benefft in the sciences of biochemistry, biology and rek8te%Y disciplines (but only In 50 far as such related dtsciplinès arè ancillary to the main obiectl, by all surtablt means and In part￿vIar by. holding and arranging congresses, training and educalional courses on malters connected with "ochemislry and molecular biology and related dFsciplines. faciif(ating and supporting the exchaNJe of scientific information befvrten bi*chemists, mkcular biobgists and scienb.sts working in reL8ted disaplines generalty and èspeaally in Europe and other eountries of Constrtuenl Souetses facilrtating and supporting the training of young scientists in research. in the form of lellowships,. and organisin9 the editing and publication of sc*nb'fic ￿searCh and educatKJnal material in biochemistry and molecular biokJ9y and related disciplines. Actlvftles The followng paragraphs and thèir assoc43ted append￿5 ouuirtè aetivthes in X)22 frorn the diffefent Committees and Working Groups of FEBS. Exten5we inlormats.on on FEBS woth is also available on the FEBS website at wM.lebs.org. and hvJhlvJhts appeared in the ￿sue of FEBS News (pdf magazine) in 2022. vhw4.febs.orgln¢w511ebs-newsllnwgaz￿eI. Scièntlffie publrcations FEBS owns lour purna15 for the publication of re5eafch papers. Teview5 and discussM in the molecular lrfe s¢i?n¢¢5." The FEBS Journal. FE8S Letters. Molecular Oncology and FEBS Open Bio. They are published on behaW ol FEBS by Wiley and aim to PrO￿de highqualty peer rewew. fa51 publicatson, and a variety ol enhane•d fratures for both aulhors and readers. The joumals prowde n￿$t ofthe income to fvnd FEBS. other a¢lNities. The Pub1rcalio￿ Cornirtlee oversees the operttion and devek)pffÈnt of FE8S' Journals and in 20L was under the chairmanship of Johannes Buchner. Al four Joumals are intemati￿a1IY recognised to be ol high qualty as detsiled below. The four iouma15 are fully digital and can be reached through the FE8S Press platrom {￿W￿.1tbsPre$s.cOrnl. The FEBS Press ioumaLs have errt)raced changing publBhing practices and offer simple submission in any formal and a smooth publieation process, with peer review managed by editorial board members who are exp•rts in the field. Thorough ethics and research integrty checks are run by our èxperieneèd èditorial $laff prior trj article publiration. All journals nsm publtsh p*eT review feports aloft9s￿e research art￿les. Authors of arti¢le5 rejeetèd by one FEBS Press joumal can choosè to have their manuseript automatically transferred to another All itsumals offer open access options". over 60% oftotal athles published in 2022 were open access {vs 59% in 20211. The FEBS Journal Ivthv.febspumal.orgl publishes high-qualty fvlklength research papers relevant to the M0￿cular, cellular and biochemical life sciences. The joumal a150 publishes a diverse portfolio of commissioned fronl-half content revwi and edrtorial content. including State-of_the-Art Reviews, Commentaries, Discovery4n- Cgnlext Reviews. Structural Snapshots, Vievfj>oints. Word>of-Advice guides and inteNews with eminent suentists (ln conversth.on Wrth . .). Key metn'cs for 2022." Irr*)act Factor 5.4, c(¢eScor8 10.1, Crted Half4ile 8.7 year5, Medrdn time from subnNsS￿n to first decision after peer rewe•V 38 days. In 2022. the purnal publishèd 470 articles in 24 i55ue5. Authors have the opb.on of publishing their opèn aee&s$. FEBS Letters IvMw.febsletters.orgi, publishes research Teptsrts (both short LetteTr and fun4en9th ath"clesl that significantly impart and advance kn￿￿edge in the molecular biosciences.. edrtorial spee¢J is a key fealure of the journal. The joumal also publishes a dNerse range of Revie4￿ (including In a Nutshèll and Per5pectivesl and other fronl-hall content (Comn*ntaries. Stsentsts. Forum). Key melri¢s for 21)22." Irrpact Factor 3.5, CiteSo)re 7.0. Crted HaW-Life 16.8 years. Median b.me for $ubrri$sions to first detysion after peer review 22 days. Page 3 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES {A Company Limited by Guarant&l TRUSTEES. REPORT ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022 In 2022, the joumal published ￿ aftides in 24 ￿Sues. Autho￿ have the option of publhshing thèir article open access. olecular Oncology (W¥￿V.n>)￿nc0I.orgl publishes hrgfviryiact Tesearch articles in basic, tran$￿tIonal and clinical cancer research. Thè joumal also publishes corrmtssioned ￿￿ewS and policy papers discussing en*rging concepts in cancer research, caneer diagno&s. prevents.on and care. Key metrics for 2022. Impa factor 6.6. CrteSeoi• 11.8, crted Haif4rfe 4.5 yeats. Median b.me from submission to first dttision after peer rèview 41 days. In 2022, 230 a￿"¢It$ wefè published in 22 issues. The Joumal is full open ac￿sS. FEBS Open Bio 1￿m.￿b$oP￿nbi0.0rg1, publishes research a￿"tIeS aeross thè molecular and cellular lrfe sciencès. v4rth the emphasis on lechnical and eth￿1 qualty rather than subiectNe judgements of significance. Research arbcles on Education in the n￿leCUlar lrfe sciences are published free of charge. Key metrics for 2022 Irrpad fador 2.6. Crtescore 4.7, Crted Haff4ife 3 7 yea￿, Medi8n brre from submission to first deeisitsn after peer rewew 33 days. In 2022. 171 articles wère pU￿ished In 12 issues. The journal is full Open Acce5 The FEBS Networ* The 'FEBS Ne￿ork, plarform. 111 hosts blo*type posts offenng insight advice. nthys and comirEntaries for molecular life saentists lunder the Iherre5 Early-carèer Scierrtis( Educator, v￿WpOInls and Rgsearchl, and 121 supports the devebpment ol an online comrThJnty of scienkn.sts through presentatbon of profiles, and fun¢tsonalrties su¢h as folbwing. commentin9 and open or prwate rooms. It also offers a channel for posts and a prNate room for FE8S Conslrtuent Societies, and hosts vide05 such as interviews and recorded talks. The FEBS Nefvrfoth in 2022 was overseen by the FEBS Nets￿r￿ WorkJ"ng Group. comprisin9 suentssts delegated from other FEBS Commrttees or elected and chaired by Prof. Xavier Coumoul. Wiley had offered collaboration to develop a FEBS Netmrk in thejournal Publishing AgreeTh￿nI 201￿2023 and bears the cost ofthe 50fvrfar• provision from the plarform prowder. Zapnrto. The current aims of the FEBS Nebvofk include111 supporting and enhancing the key FEBS activities ofjouma15 and events. as well as Othei FEBS th 5u¢h as education, science & society and fellowships',121 provTding an innovatve offering from FEBS as a new way to support the molecular life sciences community. and131 building more aeeess to Sc￿nt￿tS Interested in FE8S adNities. FEeS Fellowships The report from the 2022 Chairnwn of the Fell￿shIpS Comfftttee, Prof. Alain Krol, provides information on the range of applI￿tIOnS ￿CeNed lor the varwjus categories of FèlhJw5hips. Foll¢Mry the final call for Long-Term Fellowships ILTFI in 2020 (when 77 applicatK)ns were received), 6 new Felk)wships were awarded and were taken up Irom January 2021. the total in post Ojring 2022 wa5 S (Appendi¥ 41 the LTF'S final year In post 1$ 2024 39 éligible Short4•fm Fel¢)w5hip5 ISTFS) applications were recewed in 2022 and 22 wei¢ awarded. These funds enable acb.ve young scientists to work for up to ￿ or three mnths in ￿bOrator￿e5 in another FEBS country. In 2021 31 eligiblè SurT¥ner Fdlowship applications were receNed and 10 were awarde¢J to prom15ing Ma51¢rsTrhO students to promde a LaboRtory exper*nce. 5 Collabor¥tNe Experimentsl Scholarship ICDSI applications were ￿CeNed in 2022. ofwhich 4 wère awarded." the aim of the CDS Is to prowde PhD students and ywng 5cienb.sls from HINARI IResearch4Lifel ￿untrieS wrth travel and daily allowance so that they can carry out experiments which would bè impossitAe in their heme counkn"es. FEBS Excellence Award The first call for this new progrem was wAde in June 21r21. This award is intended for early-career 5¢ienb"5ts who have been estsblished in a salaried capacty in a host insbtution of a FE8S Constrtuènt Society as a Principal Inve5ts'gator IPII for al kast one year. The Award is endowed %Mth a É100,000 grant for 3 years to be used exdusivèly for purchasing consumabl•lequiprrenL In 2022. 16 eligible applications were reeeNed and 10 ￿r+ award611. Ukrainian Short-Term Fellowships IUSTsl'. thest were introduced in sprin9 2022 to help seiènli5ts in or displaced from Ukrainè. They support visits to a host laboiatory for up to 4 months. The decision for acceptance is given rapKlly- usually wrthin 3 week5 01 applying. 10 USTS were awarded in 2022, the majority of them for a 4 monlh period. and OttaSK)nally for 3 months. Page 4 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limited by Guarantee) TRUSTEES. REPORT ICONTINUEDI FOR THE YEAR ENDED 31 DECEMBER 2022 Advanced Courses Followng the COVI1>19 pandem￿, 25 pewnal events took place in 207218 Advanced L•etu(• Courses, 7 joiTht FEBS-EMBO Lectu￿ Coutses, 3 Pracbcal Coursès. 2 PractKal and Lecture Coutsès and 5 Workshops) wth continued EMBO and IUBMB support FEBS Athanced Courses prowde research updates and tèaching from scientific leaders in a pathular field and are pa￿"culaty valuable for eady-career re5ear¢hers. Interaction gf particrpant$ wrth experts and pe¢ts is ts¢ilrtated through • valhety of sessK)n forTn*S. In 2022. grants to course organIse￿ tolalkd approximately E416,C￿. FurtherrrK)re. Youth Travel Fund IYTF grants, which m 2022 totslled E90.l￿o. wère gwen to support part￿"path0n in Athanced Courses to 81 young members of FE8S Conslituent Societies from outsi(Je kne host country 119 YTFS were given in 20211. In addition. 8 IUBM8-tsansL￿nline￿tsI YTFS suppgrted the p4rb"¢ipatson of Students ou151de FEBS aièa. A eollaboratK)n continued befvleen FEBS Athnced Courses Comrruttee and FEBS Letters. which w85 initiated in 2019. Organisers are encouraged lo partKipate In prowding high-quality materkal in a form of a Special Issue or Virtual Issue in order to provide the course organiser5 the OPp￿tunrtY to gain broad vp51bilty of theirwork in well-reputed journal_ Th• 46th FEBS Cong*e5S The annual FEBS Congress is overseen by the FEBS Congre55 Counsellor (who, in 2022, was Prof. Miguel A. De la Rosal, joinyy with the Secretary General Ivtho. in 2022. was Prof. vaclav Paees. The 46th FEBS Congress was held jointty wrth IUBMB and PABMB, as one singte global event named Thè B￿Cherr￿Stry Global Summit, which took place from 9th to 14th July 2022 in Lisbon, Porbjgal and was hosted by the Portug4Jese Biochemical Society ISPBI. The Congre55 btd was accepted in a vote by the FEBS Council at their meeting in 2018 an¢J was due to be hekl in 2021. but, due to the ongthng Cov1￿19 pandern￿. the CorMJress was postponed to 2022. Despite the irnpaet of Ihe pandemic. war and rigng infiabon. the Congress attractéd 1.350 participant5 trom 62 countries and the event featured an attractNe scienb.fic prograrn comprising 12 plenary lectures. 36 symposia tOPiC5 arranged under 7 broad thew*s. 49 inMted symposia speaker5. 6 special sessions in¢ludirrtJ Research and Career Ski115. Science and Society. Edu¢ab"on and Gtrnder Issues and 109 short tslk speakers. The program also featured 902 posters from the submrtted abstracts. Following th• decision taken by FE8S Council lebborated below). FE&S P￿￿ded 5pecifjc additional funding support for Ukra5ne s￿entistS or displacetj from Ukraine vkno afe subn￿Ing abstracts to th• IUBM8-FEB>PABMB Congress. In addition to pravhding a grant forthe organ￿atitin of the Congress. FEBS eontinues to support thè pa￿.￿patIOn of young scientists at the èvènt thrwgh Congress bursaries and through rts Young Sc*ntssts' Forum avrdrds lusually 100 partKipants, including the organi&ng corrmrtteel. FE8S pro¥id$s $upport wtth r¢du¢¢d registration fees for FEBS members of Hinari B countries in the FEBS area cal￿￿ the Sprinzl Schen*. Congress Mana9ement and o•velop￿t and fvture Congresses Wth the postponed 45th Congress hekj in 2021 and 46th Congress held in 2022, the subsequent FEBS Congresses and Young scienkn.st FOrUn￿ IYSFI ￿[e a150 POStpone(J by one year as follows.. the 47th FEBS Congres5 and we¢ed1￿j 22nd FEBS YSF wll now be tsking place in July 2023 in Tours, France fo11¢)wng a de¢tsion tsken In March 21)r2. bythe FEBS ExeeLrtNè Coffttnittee and ertdo￿ed by FEBS Council, regarding to cancel the 2tr23 Congress host localion of Moscow, Russia in light of the Ru55ian attacks on Ukraine land suspension of Ihe Russian and 8dawskqn 5o¢ieb"es from FEBS actwrtiesl. the 48th FEBS Congress bid from the ltslk8n SocEty of 8iochetYtsty and Molecular Biology ISlB} was approv￿ and will tsk• place In Mik8n, Itaty in 2024. weceded by the 23rd FE8S YSF. FEes conb.nues lo takè out a cancenation insurance polw for each C0ngre55 and, atthough event insurance cover ha5 changed because ofthe COVID-19 pandem￿. FE8S conttnues to take out this insUrar￿e policy. as an exanple of FEBS, responsibilities as a chanty to manage risk and effectively delNer rts awns, along with th¢ Page S THE FEDERAThON OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarant*) TRUSTEES. REPORT ICONTINUEOI FOR THE YEAR ENDED 31 DECEMBER 2022 Contracts in place wth the Professional Congress otganiser IPCOI and Host Society. Young Screntists. Forum {YSFI The Chairpèrson of the Working Group on the Careers of Young Scientists, Prof Irene Dlaz-moreno, and an 0¥9an15Ing commrttee of ￿Ung sC￿nt1$ts organise the YSF. The 21st YSF took place in Conjunction wth IUBMB and PABMB and was hekj in Viffeiro. Portugal 6th - 9th July 20T2 209 applicat￿nS were receNed from 27 countrie5 and 110 Pfe-and post41octoral young $uenti5ts, In¢luding 11)0 ffom FE8S member societies, representing 33 countries from all over the world Including 26 FEBS membèr society eountries, attended the event. supported by grants from FEBS. IUBMB and PABMB. The progrnm consisted of 4 Keynote Lectures. 9 'YSF Career Speak•rs' across 3 session5 on 'Career Skn"Ils', 'S¢ience frgm another potnt of viev/ and 'F¢llrMships In5KJhts', 3 Seleded Oral COrrffnun￿at10n ses*ons. Poster Presentation sessions, as well as social actNrties. YSF participants also attend the COng￿S$. durin9 the YSF 8ftdge èvent was hehy. In conjunCt￿n with the decision to hold the 47th FEBS Congress in Tours. France. itwas abo decided lo hokl the 22nd YSF in the same location on 6th to 8th Juty. to be followed by the Congress. This event w8$ orgonised by the Chairperson and an intefnational oigani5ing etsmrryttee ol young sc¢entBts. ENABLE Durin9 the period 2017 to 2021, FEBS and IU8MB were the main sponsors of the ENABLE events. As agreed in 2021, forthe event organisation, FEBS and IU8MB will work with the ENABLE core partner EuTope8n institut8, who will bè appointed fdk)w"ng an open call for bids and who will act as the host and take re5pon51bility for the Symposium each year. There wll also be a Sc*ntffic OrganLsing Committee and Local Organising Commrttee. The agreement runs from 2022 to 2025. The FEWIUBMB-ENABLE Symposium 15 held in Europe in 2022 and 2023. outside Europe in 2024 ar￿ in Europe again in 2025. Travel grant support vrill be provided to young sctentists. The FEB&IUBM&ENA8LE 2022 conference, wrth the tlue "The perfect tandem.. H¢)w teehnology expands the frontiers of biomedicine.. was hosted by the Institute of Biomedicine of Seville IIBISI. in Spain. on 1￿16 November 2022 300 young researchers participated from 31 countii•s wrthin and outside ol the EU. The conference induded a scpèth.fic symposium but also outreach a¢Xwities for the general public and a ded￿ated career day. 10 Sponso￿ 5UPPQrted this intstNe and théir eonIn"but￿n allowed support tg be gNen for a totsl of 74 travel grants. FEBS 3+ Meètlngs •nd FEBS National Lectures FEBS support5 scientific events of rts Constrtuent SocEties through the FEBS3+ meetings program and the FE8S Natsonal Lecture schemè. ¢verse¢n by the FEBS CC￿gresS Counsèllor (Prof. Miguel A De la Rosa In 20221. The FEBS3+ meetjngs program provK1è5 lunding lof meetings or9antsèd through collaborations of at least three FEBS Constrtuènt soC￿tIeS. FEBS approved applicab"on$ lor trtrt) FE8S3+ meetings which took place in 2022. The Machines on G•ne5 meeting h05ted by the Biochemical Socièty IUKI and held in Alicante. Spain in conjunction witti NVBM8 (The Netherfandsl and SE88M Ispainl took place in May 2022. having been postponed from 2021 due to th¢ Cov1￿19 pandemic. This meeting featured 3 plenary speakers, 7 symposia sessions. postèr abstracts and oral tslks wth 47 poster pr￿nter$. The Meeting, hosted by the Estonian Blochem￿al Souety in conjunctK)n vnth LaBS ILaM"a society) and LBO ILrthuania society), took place In Tallinn, Estonia in June 2022. The meetirrfJ in Estonia included 210 participants190 from Estonia. $8 from Lithuania and 3 8 from La￿al. 4 plenary talks arrKJngst So se￿nt[fiC talks including from graduates and PhD-level sci•ntists acfOSS six single and parallel sessions. as well as 77 posters and industry support. FEBS support ¢onsists of 10,000 to the host society for general meeling organi58tion and É10.(￿ to support thé attendanee of young scients.sts from the other partiapating societs"es. In 2022, FEBS supported 10 FEBS National Lecture5. by fvnding the attendance of key speakers from a different FE8S county invrted by a FE8S Constituent Society to their natKJnal meeting through FE8S National Lecture Awards. The len FEBS NatKJnal Leetures were awarded to national society meetings of thè member so¢ietie5 of Croatia. Cypnts. Finland. Frarteè, Italy, L8fvba, Spain, Swedèn, Tunisia and Turkey Ifollowng the postponemènt of many national society m¢$tings duriry the Pande￿). Page6 THE FEOERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Cowoany Limited by Guaranteel TRUSTEES, REPORT ICONTINUEO FOR THE YEAR eNDEO 31 DECEMBER 2022 Othèr èvents In the Iramework of prorrnting FEBS, journals and FE8S' collaborations wfth related international Organisat￿n$ of molecular lrfe sciences, FEBS continues to SUPPOfL through sponsorship ol events and travel costs for distinguished speakers to deliver leetuies * annual meetings of leamed soueb.es of bioehemistrylmolecukr b10￿9Y1cell biology in parts of the ￿1)rfd wrth rapylly devebping contnbub.ons to mobecukr lifè sciences research. Science & SoeS•ty IS&S) The Science and Society CoTh4ttee aclNTtses in the year 2022 included.. the S¢ience and so￿ety Special Session at the IUBMB-FEBS-PABMB Congress in Lisbon, July 2022 on 'RNA SolutK¢ns to genetic an¢Y Infectious diseases, featuring inwted speakers from The Netherlands, Spain and the USA., expanding on the topic ol'Plastscs" revolution, pollution and substrtution. from the 2(r21 FEBS Congress by providing support to constrtuènt SO￿ety Èvènts and activ￿.•$ on this theme bèing hèld in 2022. Following call for proposaLs, the Science and SoC￿ty Cowffi￿ee prowded grants ofÉ1.SCKI to the Itahan Society of Biochemisty and MOlecu￿r B￿logY ISIBI foc their Publ￿ engager￿nt evenl'l'm in plastsc". if5 not fantast￿. in November 2022 and to the Spantsh Society fof Biocherristy and Mole¢ular 8iology ISEB8MI for a wdeo project enbtled'How can biop1astics contribute to diminish plastic pollution?. part￿lp8t1on in 8iomedKal All￿nce act'vth'es. Through actNe participab'on in aCt￿rt￿$ ol Bion*d Alliance (General As$¢mblies, Policy officeis, meetings and ts5k forces) the S&S ComThottee contributed in several Suggested documents for the shapirrfj of Eurctpean polKy. including part￿lP*"n9 wrth other organisab'ons to obtain from the EU tht btst research bu¢Jget t*rth* Franwork Program FP9. ParticipaiDn in the FEBS N$tsYork. Education The Education Committee has the rnission of prornb.ng edu¢*"on and training of the highest quality in rnolecular life Se￿nCeS in Europe at both vndergraduate and Frtjslgradvate levels. The commrttee's actiwties include.. organising and ftJndin9 edueatlort events, running the EdU￿t￿n Ambassadors initiative, supporting the open access journal FE8S Open Bio's section devoted to education and overseeing and contributing to th• Educator Channel on the FEBS Nètsvork. FEBS Education Commrttee also works col￿boratIV￿Y w rth FE8S AdvancedCourse5 Commttee and FEBS Woiknng Group on the Careers of Young Sciènts"st$_ Thts rs the report from the Chairperson, Prtsf. Fethan Sajin on Education Commrttee actNi(ies planned for 2022. Education Commltte• Meetings: Ihe committee met in-per50n in May 2022 in Izmff, Tortrye (for the first lime since the pandemic) prior to the Ambassadors Meetyng., a second eommrttee meetin9 was hèld in October 2022 in SlbeniK Croatia, pnor lo the EducatKJn Workshop event Four onlin& mthngs ¥￿Te also held. 6th FEBS Education Ambassadors. Mteting The 6th FE8S Education Arrtjassadors Meeting took place in Izm"r. Tiirkrye on 19 - 20 May 2 022, wrth 28ambassador5 in attendance. Thè meeting program included on day o ne.. 5 short prtssentations from ambassadgrs sharing their educab.on athvr(ies in thè past year, a panel dt5cussion wf(h three talks focused on the history a nd aims of the Ambassadors Inth"*ive. the irnportance of education in the mission and vision of FEBS and the roles an¢J fvnth.ons of the Ambassador5 based on the 2021 SWOT analysis vndertaken, followed by group actmkn.es on speof c Ihemes.. and on day two.. a tslk on 'EdueatKJn research and challenges aehiemng publication. foll(wrtd by g roup act¢vilies on specific themes and a final talk on 'a¢¢reditsbon of rnolecular bios(xen¢e degree5 in Europe,. Edueation corrmi￿ Seasonal IN•blna The seasonal webinar series which stsrted in 2ff21 ¢￿tInued in 2￿22. wrth.. Spnng webinar entitled 'Visual¢ati¢rt in 5rAerKe ed￿alKIn". erne1g￿g opportunities kn making the invisbble visible Summer webinar entrtlèd'How to SUPPOrt sustsinable supervision of doctoral resear¢hers'; Autumn webinar enbued 'Devebpment of a tea¢hing Tr￿dUle lor PhD (andidates." and Winter webinar entrtled 'Asse55ment 101 beyont1 in Lrfe s¢￿ènCes ed￿￿t￿n.. Page 7 THE FEOERATION OF EUROPEAN BIOCHEMICAL SOCIETIES {A Company Limited by Guarantee) TRUSTEES. REPORT {CONTINUEDI FOR THE YEAR ENDED 31 DECEMBER 2022 46th jolnt IU8M84EBS4ABMB Congres8 Education Acti¥itRs FEBS Education CoMM￿ee organised its tradIt￿n81 spec¢al and poster sessions joinuy with IU8M8 and an èducation plenary jointly the Congress Organiser5, at the 46th joint lUBm￿EB&PABm8 Congress. 11 FEBSIIUBMB Speaal Session on Edueatson entrtled 'Where do WÈ go from here? Experiences, lesson5 leamed and projections for hybrid post£ovit1 education, wth speakers from Spain, Australia and the UK. 21 Education Ptenary lectuie entrt￿d 'Beating to a diffarent drurn. how can education beeomè rèlèvant again?, by Boris Jokic (Croatial 31 Postsr Session on £dU￿tiOn- 22 poste￿ We￿ submrfted on education. 41 FE8S Special Session on Research and Cafftr Ski1I5. ￿ganISed with the FEBS Wor￿"ng Group on the Careers ol Young Scientssts. Contribution to FEBS Network Several posts were published on thè FEBS Netswrk Educator channel in 3)22, includirrfJ." 'Decreasing fear of failure and in¢fea5ing meaningful intèra¢lions with students. 'Integith"ng Augmentèd Rèalty into bioscieneè educab"on' 'Stepping outwde olthe catch-22- tips foi bioscientists comrThtted to education. ain recggnrtK)n lor your innovabons usirKJ dwrtal tools In saence education. 'Using Pèbblepad for e-portfdios in the r￿￿al scEnces' 'Visual asynchronous teaming ￿terIals.. examples from Edpvzzle and ThingLink' 'Translerable skills education in the biosciences". weparing our graduates for life outside uniwrsit Educatlon Committee Wortt$ho FEBS Education Joint Workshop wilh HOBMB Icroalian socw) held in ¢)ctgber 2022 in Za9reb, Croalia. ¥￿th the htle'Designing Educational Reseaich.. FEBS Education Commrttee also sponsored an education workshop organised by tha Tunisian Education Ainbassador. Hatem Fakhlakh. ent￿ed 'EduCat￿nal Consid•rations for Training, on 7 Decemb¢r 2022. Contributions to the 2022 IUBMB-FEBS•ABMB Young S¢*ntists' Forurn ThÈ Educats)n Convnrttee participated in fvdo prathcal sèssions of the 2022 IUBMWFEBWABMB Young Scientists. Forum (held in Vimeiro. Portvgal to the joint CoThJressl. enlit￿d 'Career Skills Practical Éxercises.. Contributions to FEBS NAvanced CoU￿S FEBS Educats"on Committee chair gave a Iraining le¢ture on the science and art of writing a scients"r￿ artic￿ at the FEBS Advanced Course'Redox ￿terationS and Cellular Responstt". From Signalling to Interventions,. I￿25 September 2022 Spetses Island. Greece. Two workshops lon how to wrrte a scienfft paper and h)w to present y)ur wothl wo1& ￿TrIed on at the FEBS A¢fvanced Coufse .360" LY￿Son￿". from Structure to Genomics. from FUnd￿n to Diseèsè. 4 - 9 October 2022 Kusada5i I Izmir. Turkey. Integration The Working Group on Intègratb)n IWGII. wh￿h vms chaired in 2022 by Prof. Jerka Dum￿, continued its outreach and support for scEntists In European wuntries with econornic challenges andlor no existing or a¢tNe biochemical soc*ety. as well as aclmtses for Inte9rknn and collaborat￿) ty¢￿￿ all FEBS socreties. ActiMt*s ofthe WGI d￿n9 2022 induded.. working Wrth the FE8S Fellowships Comftmttee on the ColkboratNe Developmentsl Scholarships criieria for the exeluswt benefft of PhD sbjijents in eertain FE8S eountrTres Wrth HINARI IResearch4Lifel status.. supporbng the three societies ol Estonw, L8fvN4 and Lfthuania wrth their organisation ofioint meetings. wrth their next meeb.ng held in Tallinn. Estonia in June 2022", launch ol the Member Sotièty Representative5 IMSRS) in(¢iative'. comm?ncing in July 2022, this initiative involves one MSR from eath FEBS Jr*mber sOc￿ty to be the maH) link bttween their soeitty and FEBS to .Pago 8 THE FEDERATION OF EUROPEAN BIOCHEMICAL S(xieTIES IA Company Limited by Guarantsel TRUSTEES. REPORT (CONTINUED) FI￿THE YEAR ENDED 31 DECEMBER 2022 strengthen the relatvnship, as well as providing a voice to keep FE8S inforn*d and the opportunrty lo ne￿ork wrth the othef MSRS via a dedicated FEBS Netswrk channel, in online meetings and in person al the annual MSRS meeting held in conjunction wrth thè FEBS Cong¥Èss 2022 was thè first pilot year ofthis inrtiabve. FEBS provided limrted support to each MSR for th$m to attènd the Con9iess. Al member societies lexcept the suspended Russia and 8elarusl have nw4 nominated MSRS and 30 ofthè 37 MSRS attended the Congress in ￿5b0Th and MSRS rrEetin9. the WGI Chair attended the FEBS-IUBM8-ENA8LE kick-off ￿eting in Cdogne. Germany in May 2ry22 and the Education ComrThttee n￿ding and Education Ambassado￿ ￿ting in Izmw. Turkiye in May 2022. the WGI Chair actively on new inrtiatNe5 to increase collaboration and engageTh*nt wrth FEBS member sotseties and ¢¢ll#bo¥ated wrth olher eonynrtiees and working groups. As part of thè WGI aLIMties and the FEBS Congress, finaneial support was gwen under the 'Sprinzl Seheme, wrth a SO% registration fee discounl to scienb"5ts resident Istudyngthrkingl in Arrrenia, Bosnia and H8rz89ovina. Ggorgia. Moldova. Morocco. Serbia. Tunisia and Ukraine to attend the 2022 Congress. Women in Sclence The planned actmbes ol Ihe Working fyoup on Women in s￿"8nCe (WISE) wth Prof. Ceeilia Arraiano as Chairperson in 2￿22. wefe as fdl¢)ws- The FE8&EM80 Women in Saence Award, in rts fffteenlh year, recognises and rewards the exceptional achievements of a female researcher in molecular ￿OlOgY giving particular attention to the previous fve years. Winners of the award are role models who inspire future 9eneratr.ons ol wOff￿n in science. The 15th meeting ol tr¢ FEBSEM80 W(Ynen in Science A￿rI ¢ommtt$e took pla¢$ m February 2022 to reV￿W the nominations receNed fof Thè FE8SEMBO Wow*n in Science Award 2022. Many of thè candidatès, Cvs weie excellent. Aftèr discussion. the working 9roup votèd lo award the 2022 prize to PTof. ETin Schuman (Frankftjrt, Gernwnyl, for her •xcepbonal contributions to our understanding ol nèuronal cell biobgy. The awafd was presented durin9 the FEBSEMBO Women In Se*nce Award ledure at the IU8MB-FEBS-PABMB Congress, held in Lisbon, Portugal in July 2022. The working group also pknned thè folbM"n9 events at the Congrw" al the FEBS Spec￿1 Session on 'Gendei Issues in Science. with four inmted speaker5 and an open dI5￿$S1on. bl Ihe The￿orkIn9 lunch for 50 Congress parttcipants to discuss Women in Science issues OBJECTIVES AND ACTMTIES FOR THE PUBLIC BENEFIT The overall gbjective of FEBS is to contribute to and prorrKJte the advancement of research and education for th& public benefft in Ihe sciences of biochemi8try, mlecular bKJty and related disciplines. As indicated by thè spo¢ifi¢ key objectives of FEBS set out above under Dbjectwes.. FEBS doès this particularfy through". funding forums for presentation and discussion of research r8suMs and r•lated areas of interest al rts large annual Congress, Young Sc*nbsts' Forum IYSFI. FEBS Felltsw5 Meeting, Special Meetings and other Advanced Courses.. promots.ng training through lectures u)urses. w9rk5htsps and prarti¢al courses ol its Advanced Courses programme, as well as rts èducab.on workshops., and supporting participation of pfomising young scientists in these evenls throu9h YSF aw8rds. Youth Travel Fund grants and Congress bursariès., facilitating and suppth.ng the exchange of s¢*nlthc infornwlion betsveen biochemists and moleeular biologists especially in Europe and other countries of FEBS Consb"tuent Societiès principally through these foiurrts and rnechanlsn￿, but also through Constr(uent Soeiety meetrngs (National Leclur¥ stheiiiel, FE8S3+ meeb'ngs, FEBS Fellowships (which protTr)te n￿bIlty), and s¢hemes to 5UPPOrt integration of bioscientists working in economicalty disadvantsged countries ofthe FE8S area.. providing skn'pends through rts Fèllowships progrtmme to all￿￿ research to be carried out in host laboratories by talented early-career scientists." offering high-qualty publication of research findirss for both authors and readers through its four internat￿n81 molecubr life science ioumals. Page 9 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarant*) TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 31 OECEMBER 2022 Through the many aCIN￿e5 of FEBS ouUin•d above. the beneficiaries of FEBS include seièntists at all levels directty enga9ed in resear¢h educatK*n in the mole¢ylar life styences, and ulh"mately humankind acros5 the globe through the contributions of these areas Clf suence to human h¢aMh, agri¢unure, biotechnology and related a￿&$, and enriCh￿0t of human kno%￿èd9è. FEBS vtholty owns r(s intemational ioumals, are ol importance to FEBS bolh by directly contributing to its objectives and as a source of income to support rts othtr purposes. FEBS follows all directives on Open Access publishing from the UK, EU and rekvant research bjnders across the worfd. of the FE8S publicat￿n5 - FEBS Opgn Bio and Molecular Oncokngy- are fvlly open access. tts two hybrKI journa15 - The FEBS Journal and FEBS Lèttèrs - offer author5 open aecèss opt￿nS, often wrth no ¢Jireet cost to authots at Instrtuts'ons wth a tran51ormatK>nal agreement In addth"on. authors are ab￿ to deposrt accepted research artic￿$. as ¥equired by funders. in institubonal repositor*s, through which they are accessible to the public. and all published arti¢les in our Joumals are freety available after 12 months to all reader& FEBS events are nomialty open to scientists throughout the worfd. Reupients of FEBS grants for fellowships and for 5UPPOrt of parttcipatson M) mtetings are norrywlly required to be members of FEBS, Constrtuent Socieknes where membership criteria are those expected ol leamed sOc￿tIeS) and reS￿ent wrthin the FEBS area of Euiope and neighbouring counthes. Som? FEes pith3raTh￿ partsculaty benefrt disadvanta9ed Scienbsts. The trustees confim that they have referred to the guidan￿ cofttsin¢d in the Charty C ommi55ion's general guidance on Publ￿ benefft when r￿t￿n9 the organi5thon's aims and objectwes and in planning luture actiwts"e$. Grant Maklftg Policy Thè overall objectNe of FEBS is to contrit)ute to and promote the advancement of reseafch and Èdueation for the public benefit in the rn0￿¢￿1ar life 5¢iences and related disciplines. Polic*s for key grants awarded by FE8S to achieve these goals ale oUtI￿ed below. Fdlowships As part of our commrtment to young sc*ntists uThJer the FEBS F¢1kn￿hlP progfam set up in 1978, and to further research in the molecJJlar lifè s¢i¢nces, wo offèr Short-Term Fellowships tg members of Constituent So¢ieties, as wèll a5 Summer Fellowships to profftsin9 MastèrslPhD students. The FEBS Ex¢ellen¢e Award program vrd5 launched in 2021. It is Inte￿Ied foi early-career ￿len￿St$ who have been Pls in their Host Instr(ution for at least one year and are in a salaried capacity. As part of our Fel1¢Y￿h1ps program, we a150 offer 5¢holarship$ designed exclusNely for members of our Con5b"tuent Societies based in FE8S counliies wrth HINARI IResearch4Lifel status. Ojr Fellowships are intended to allow Membe￿ of our Constituent Societies wothing in FE8S country to work in a Paboratory in another FEBS country. Eligibilty critella FEBS F¢lh*vships a￿ set in detaI￿d guidelines on the FEBS websrte. The initial applications lor Fèllowships are asst55ed on rrerii by the FEBS Fellowships Comrttee. Within three months of corTyletion of all Fellowships. awardees are required to prepare a final report on the work carried out during the tenure of the Felbwship. Similady, EX￿llenCe Avrdrdees are asked to provide both a seientfft and a financial report to be digible lorthe 2nd and 3rd insta1rr￿nt5. Grants for organising FEBS Advanced Courses Grants for organising FEBS Al￿an￿¢s Coursès lincluding kcture coutse5. workshop5. practical courses and special meetings) are awarded to senior scientists by the FEBS Advanced Courses Committee on a competitive basis Reports (including scientific and finanuall from the organisers are required wthin 3 months afterth¥ event. Grants for young scienlists attending Advanced ¢¢urses students parti¢ipaling in FEBS Advanced Coutses lineluding ledure etsurses. wowkshop5 and practical courses) may appty for financial support through the FEBS Yovth Travel Fund {YTF}. In 2022. grants were made to persons travdling from their current country of Te5idence to another country. mostly in the European area. Page 10 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarantee) TRUSTEES. REPORT {¢ONTINUEO> FOR THE YEAR ENDED 31 DECEMBER 2022 Applicants for these grants shoukl nollnally be registeret1 as a student at an institution of higher learning in a country where there is a FEBS Constituent Socbety or be %wthin fve years of having completed a Pho thesis, be a member ol a FEBS Constrtuent sOc￿ty, aThJ not have reeeNed a grant from the Youth Travel Fund to attend an Advanced Course in Ihe ¢uThenl or preceding ￿ar or received a granl to attend Ihe Young Scientists, Forum in the currenl year. Candidates are shoruisted by thè Coursè organisers on Tr￿lIt. Grants for oryanising th¢ FEBS Congress and FE8S3+ m¢¢ting$. and requests for National Lecture support FEBS ￿alUateS bids for organisin9 ts yearfy Congresses and a150 FEBS3+ mèèlings. as well as raquasts from Constituent societs.es for N*￿lla1 Lecture support. a￿OrdIng to their quality.. the administrative rtsponsibilrty for these Is in thè hands of the FEBS Cr￿greSS Counsellor (Prof. Miguel A. De la Rosa In 20221. Grants for attending the FEBS Young Scientists. Forum and cong￿5$ IYSF awards) ReCIp￿ntS of YSF awards arè selecled by the Chair of the Worknng Group on the Careers of Young Seientsts Ilrene Dlaz-moreno in 2022) and the local organtsng commrttee.on ft￿rit. wth eligibilty cnteria that normally include.. i)being a PhD student or postdoctoral lelbw wrthtn 5 year5 of Iint5hing hislh?r PhD at an instrtution of higher education in a Country where theie is a FEBS C£snstituent Society.. ill bein9 under 35 yèars ok¥." iiil being member ol a FE8S Conslrtuent SOC￿.. not having attended a recent YSF. and not having received a yo￿￿ Travel Fund award in the 5arre year. Congress burwi¢s Reeipient5 of bursaries (which offer financial s¢Jpport with registration. travel and accomnl)dat￿n costs for the Congress) are selectsd by the host So¢￿ty ofthat yearfs Congress on meri( eli9ibilrty Criter￿ similarto those fof YTF and YSF awards. Page 11 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA CoThyany Limited by Guarantee) TRUSTEES. REPORT ICONTINUEDI FOR THE YEAR ENDED 31 DECEMBER 2022 Achfiev•ment and ￿rnian¢e Thi5 5edion sunw))aris&s and assesses our prinopal achievements in 2022 against the forrnal obj8L*Nes of FEBS. More detsiL8 ol the activities included in brief here can be found in the 'ActMties' sectyon above. Objective 1: holdlng and arranging congrèssès. trairting and educational courses on matters connectéd with biochemistry and molecular blo1￿Y and related disciplines Ac*l•vgmpnts FEBS Advan¢•d Courses In 2022. FE8S to several Courses YltyL hlgn SaenfjT￿ ￿nient ana so YrF ￿ants 10 oiiow parlclpal￿7 ol re5earchus at the FEBS course5. I￿ni FEe>EM80 Leclure Cwr5e5. 2 Prdctth arm1 Leclure C¢JurEe5 were as pusonai evert8 Ouflng 2022. funoin9 tefi1￿1. (xllne dolabase f¢r apF4TrtXY￿ atKI ¥Eb5ites th<#JLKvJ cdIat*)tst￿rts EPAPL) aTrJ IV8M8 cNIM￿. FE8S3+ M••iiTro1'. anie. S￿n K1ay 2022". IrE NthrEs 0ftGe￿. meelit)g bosied ty the 8iLK*knI SAxiety IUK). Suw*t ty x*nli5tS In E￿onIa. Lama. LftNMnra. lE(v￿n these FEBS C￿S1￿￿eN ￿etieS. see '￿￿X￿t C4)nslitUEnt Scrjety events. seciion lor ana s￿Tr.. T*llnn Estorma. 2022. Ine h05reiJ fflewer sweiies orLakna a¥J LThban poh)rt meattenaarKeorywYJ s¢ientiSts frOrn￿ ¢X partUPallng Scr￿les. 1st Youny SCIent￿ts Fovum IYSFI and FEBS ¢ongrE%: e 21￿ Youry ScienbSI* Fon¥n. In IUBMB wxl EBS. 1001( ￿a(e. The YSF lnrJ￿ o4er 100 PhD an C￿re$S 6 ILwvJea fry FE8S YSF ai%*ras. In *￿ition. Fe8S supports pjrtkjw￿ ￿ a ￿rge olyowYJ SCW*is7s ￿ 115 anrw)I Congfe5$ unclon IUBM8 PABFAB. The annual FEBS cong.ress provioes a ptratf Icf interrwlKYbJl s(ientlfic exchallgp and S￿r¥se$ I￿ r*¥A¢st ae¥dopmen15 In b￿￿51￿. n*eculai knDb9y and areas. The Congress comprises p￿nary ieciur&8. syrnptss* po*er S￿sk)n5. IWYK5Th0PS and Olher Ml*S rMI re*ateo tot¥¢S. The c4ngRss Is wo In counthe5 a Con5tMueN sc￿ety of FE8S. Page 12 THE FEDERATION OF EUROPEAN BIOCHEMICAL s¢XIETIES IA Conwany Limited by GuarantÉel TRUSTEES. REPORT {CONTINUED) FOR THE YEAR ENDE031 DECEMBER 2022 ObJ•ctive 2.. l•ellitatin9 and supporting the exchang¢ of scientiflc infornution ljetween biochemists, molecular biologists and ￿lenti$l$ working in related discipllY*s g•n*ralty and especially in Europe and other ¢ountries of Con¥tituent Societies A¢hi&v•m•nts FEBS Conor•ss. Ath7th￿ed CouThes an(1 EdUu*￿W0r￿S L•¢tur•rs for Constityent S•¢i•ty aAa Olh•f sclent611¢ fflthtrys Mylk)rwl L&lU￿ lo s￿)elES ￿￿ernational reellr¥Js Turtya aThJ TLMW. other sponsorsnip rfeetrgs EurotE. Kfftiui intun•irna Ugartz*K￿s * ylew FE8S ￿M¥s. Aehlevem•Thts FEBS FellW￿l￿P$ FelllPh8 (see Ctiecb4E 3 WGI 5thm•s Supphyt for (￿rr¥Jn￿ ol Im￿￿￿rNIe Si￿15[$ In Ewfwn s¢ciety Ihrwjh ￿S￿$. the Ccfigress'spnnl SU￿￿. EaLfa WoNsrws CDS Fdknws as a5 enC£￿ragIThj me eStatytsl￿1xN ofngw50f*Les ano FEBS. Objective 3: fa¢llil•ting and supporting the training of young ¥cienti8ts in rese•r¢h. in the form of fellowship$ Athiev•m•nts st￿rt-Terrn Fdlow5hlp L￿- T•Th￿ FelJOWJThIps 5 L￿￿T￿ In PCGL g*ary Iwniis. ACC(￿1$ ft¢mèitsr part of FEBS e¥wL*the TMS ¢K(W￿l¥3$ aiscertln￿ as e12021. Exedi•ThC• A￿¢￿ 19¥)￿51. St￿[￿551￿. Iry rnkSI be Fecrorrizeo sctnusts Inthe F•11¢y￿ M••ttng Imd m Vime*o. Portw ￿ 2Q2z In the Young Scknitsis Fotwn) 17 pJrrEM r LTFS Ihe w)vit*th. parttwants iwieo 10 partwie. No sewon {￿￿1Ure a5 ortyctjrrent past FE8S Lor* Terni F•ifpw5 are eiyibie. The c￿￿￿113t￿ costsaTe Page13 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Comp•ny Limited by Guarantee) TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022 Objective 4: oryanislng the ediling and publication of sci•ntSfK research and educat•onal mthrlal In bloc￿MIstry and mol¢¢ular biology and related dlseiplin¢s in a W¥15DIry The current Publishing Agreement between FEBS and I￿1￿Y run5 201&2023. The eight-year contrad is based on revenue share. guaranteed incon* and SF*c￿l support for the FE8S Nets￿￿. FINANCIAL RW4IEW Journal income and costs Total income from roya￿'e$ in 2022 was 0.2% hMJher than the royalty incon* in 2021. The totsl costs lor the four FEBS journals. FEBS Journal. FEBS Letter5, FEBS Open B*) and Molecular Oncology in¢￿ased by 13% in 2022 frorn 2021 lexduding forèign exchange) Thèse costs are the ¢Jirect costs and support costs induding èmployees work on the joumals. The increase ts due mainly to an increase in joumal payroll costs. Distribution of •xpÈnditure on FE8S activities In 2022. Fellowships r*ffAined by far the highest area of charitsble FEBS spending 4894,000 {4817,000 in 20211 then Advanced Courses, gross Course grants and ￿F$ totaling 4506,oC￿,.1-97.C￿J) in 20211. PirLes and awards for excellent¢ in molecukr Irf¢ scien¢e5 totaled 439,0001430,000 in 20211, and fijnding of lecturers for meetings within and outside of Europe totssed 454,OCKI420.000 in 20211 including h¥0 FE8S 3+ n*etings. Several other areas of FEBS work induding edU￿tIOn workshops, science and SoC￿ty sessions, and 'integration' inrtiatsves, ￿￿Te undertaken for ￿￿8,[￿KIl￿16.L￿O in 21r211 in total. Governance and support costs The senior sc*ntists who serve as FEBS Offi¢er5 and rrembers of FEBS ￿rnrThttees all work pro bono, 8nd the holders of key positiofts In the FEBS Exerxrtwe Commrttee generousty devote C0nsN1erab￿ ts.mè and energy to FEBS activfa'es. There are a small numbèr of sUPPOrt personnel working in111 the FEBS Central Administration OffKe dealing with eentral administration and corrmunutKJns. {21 the FEBS Treasury orrice dealing wth fina￿la1 matters. and 131 those woth.ng the Fellovrthips and Athanced Courses Commrtttè Chairs to support their work and those ofthe ¢onNnrttees. The total govemanee costs- including Ihe expenses assoeiated wrth higher4evd commrtttes Icouncil. Execukn"vè and Finan¢el vthin FEBS. Central Administrab"on Officè. The Treasury Office and Secretary General expenses, as well as audrtor and other lees amounted to 18%123% In 20211 of th• S￿e of charitable spending in 2022 (notè that these governance costs are not included in the lotal for chartsble spending). An indieab.on of the sup￿( eosts invofved in runnin9 the b¥0 acmies of FEBS with Ihe high•st expenditu[• can be gNen by the commrttee expenses as a peicenlage of the charrtable spending in that area". this was approximately 7% in 202214% in 20211 for Fellowships, and 11% in 2022120% in 20211 lor knanced Coursès lallhough these ￿ureS exclude governance costs of central admintstrabon at the FEBS Treasury orricel. Support Costs for th6 Journa15 are covèred in'Joumal incorr* and costs, above. Investment performance In 2016 FEBS reviewed its investments and the Finance Corrmrtt¢e deuded to hohl a tent1er for the management of the inveslrrents of FEBS. JP Morgan Wd5 the successful tenderer after an intensive se￿CtIon process. The tenderwas conducted by the Finance ConYNtlee, plus the Chair of the Fellowship Committee, with the assistsnce of an independent investment con5uttant. By 31 0ecembeT 2017 the investment portfolio had bèèn moved to JP Mor9an. For th• rrKJnths to the 31 Det¢mber 20Z2 Ihe inveslment wJrtfoh'o held at Jp Mor9an had a rebjrn of-13.09% bss1+14 6 % in 20211. Page 14 THE FEOERATION OF EUROPEAN BIOCHEMICAL SOCIETIES {A Company Limited by Guarantee) TRUSTEES, REPORT (CONTINUED FOR THE YEAR eNDED 31 DECEMBER 2022 PRINCIPAL RISKS AND UNCERTAINTIES The trustees have a duty to Idefity and ￿¥1￿¥ the nsks to which th• charty ts èxposed aThJ to ensure appropriatè coniiols are in place to provNle reasonablè assurance against fraud and erroT. Change to JoLFrnal Income In add.thn to directly fulfilling one ol the charilable objectNes of FEBS Ipromoting and dissemin*ing scientific research and ideas), o¢Jriournals prowde a source ol income to fund FEBS, oth•r charitsbl• work. Future income strea￿0 are uncertain due to major changes in the pUbl￿h1Trg sector. The income fron) journal publishing 15 changing as library contracts nw¥e from $ubw"ptwJis to open acces$ publi¢*ion fees or other publ$sh￿g modeL8. FEBS is addrg55ing these concerns by {1) rts policy on reseNes (see bek)w) so that some fijture i￿Orne can be dtnved from inVest￿ntS and121 ts negob'ated long4errn contract wth a commercial publisher whieh, in turn. is negotiating dèals library and bjnding consortka for Read and Publish I Publish and Read access to the FEBS pre55 journals. A group of funders called cOAlition S mainly from Europe, announced an initiatr've (called Plan Sl in September 2018 requiThng their grant holders to publish only in full open access journals from 2021. From 2024 all publication in¢orre voll transition towar¢Js fvll Open Access. The FEBS Publications Comffittee has reviewed its consequences and made a strategic plan on howioumals ean adapt to new publishing requirements of Plan S 5UPPOrted authors. Return from investments Up until the end of 2017 FEBS followed a standard inve5trrenl policy wilh investment in 30% bonds and 70% eqU￿"eS. Since Tnoving the InveSt￿￿nt management to JP Morgan, FE8S ha$ made $omè changes to its policy wth investments eurrently 131 May 20231 allocated to 60% equi(Es, 27% ffixed it)com• and cash and 13% ¥lternativès IPE is limrted to 8%). The perlormance of FE8S' investments is monrtored ￿gUlarty. Tha performance of thè portfolio held at JPM for the year ending 31 December 2￿22 was-13.OVh1*14.6% in 20211. All decisions about investments are made by th* Finance CommrttÈe. as delegated bythe Executwe Comnrtte¥. On OcCas￿n the Finance Conwnrttee may seek further approval from thè EKeortNe Cornm￿ee on significant investment commitments. Internal Controls FEBS has an environryEntwhere improvemnts to the systems and PToeesses are encouraged. Tht Finance Committee is responsible for maintaining proper acctyjnting records which discbse with reasonable a¢curacy at any time the financial pOsrt￿n and to enab￿ them to ensure that the finanual statemeThts comply with all ststutes and regulations. FE8S' controL8 inelude regular inteinal and eytemal oversight and checks. Controls and procedures are appropriato lor the or9anisation's soe and operation. FE8S uses automated aecounting sofmre from a large, reputable supplier and The Treasury dèpartment has several processes to ensure the appropriate use of frjnds. the rnana9èff￿nt of the accounts and recoiding of all transactions. Dub"es within the Treasury are separated. and Tobust systems of overS￿ht and authorisab.on are in place. Impact on overall objectives The success of FEBS In promot¥ig the a¢fvanceff*nt of research and educab.on for the public benefft in the sciences of biochemi5ty. mokcular bKJk)gy and related disaplines 1$ ¢arefvlty monrtored by stringent peer review and other methods. PLANS FOR THE FUTURE Reserves policy Thè total value of lunds held by FEBS at 31 December 2022 was É89.3M1É99.2M in 20211. None of the funds re restllcted ftjnds or unavailable for the general purp9585 of the charity at the end of the reporting period and no material affKJunts have been dèsignated or are otherwtse commrtted as at end tsfthe reporting penod. Page IS THE FEDERATION OF EUROPEAN alOCHEIAICAL SOCIETIES IA Company Limited by Gu•rnnw¢l TRUSTEES. REPORT ICONTINUEDI FOR THE YEAR ENOED 31 DECEMBER 3022 As at year end 2022. aFpr0￿Mat￿Y 83% coukj be realised in lewtr than 3 days. was in investmenisthal may e realised in 10 years anil the re51 had lThescales. vp lo 4 monlhs, in which the a55ets may be iealised. The Inveslrnents in private eqLrity and inlrastnjaure canrnl be Squtdated. These in¥e5tmenls wll be hewj foi up 10 10years and vp lo 8% v4ill be hdd In private equily and 5% ￿ nfvaslruclure in FE8S' main pKtrtloh"o. The Trèasurer of FE8S' regularty revws the r¢rfomance of FEBS inve51rnents during the yeaf. Significant ¢han9es in Invesirnenls and Ire31menl of funds are discussed approved by Ihe FE8S F￿anCe Committee andwhere apprcpriale. are sutffiitted fN hmher apkwoval from Ihe FE8S ExecutN* Committee. The FE8S fftse￿s polw albcates É4M one Jea¢5 essen￿ lun¢Jfftg artd Ihi5 is held in cash al Ihe ban The FEBS Tw51ees aFwo¥*d the ￿hance￿￿￿1 of Ihe irNe51m8Trt Portfol￿ lo reach a value that rnay seneraie funds tt> offset polentrdl changes ￿ incrfft due 10 Ihe puWi5hing modes. The Income frtyn tl portfolio in addition to royatty income v4iH ensure thal FE8S exists in Fel￿tulty prowth'ng lunding for Ihe wnnsr olthe joumals and ils Olher thawiiable ad1¥1￿5. Impa¢t of COWD-19 In the short 10 ￿dIuM term COVIt>19 not hav8 * wrwact on majLw Sour￿ of FEBS, i￿rne which 1$ Ihe royalt￿$ frcffi FEBS. joumals. The fnanoal performance of the in￿stmen1 porrfolio gave an investment performance of 14.6% in 2021. W¢ylJ ev￿1$ including the inv3sion ol Ukiaine by Ru55ia. have had a negalwe I￿￿4£¢ on FEes ￿vestMents 2022. wih a l¥1 of 13% Yabjg ol FEBS. main portlolu?. FEBS did nol inDJi any addilwal cosls due io COWO 19 and ¢ls day-l￿daY OFeralKJnswwe carried on without a major inpa¢i. No employe*5 Ot FEBS were ￿OUght￿ and no governmenl granls were sought rece&ved by FE8S ￿ relation to cov1￿19. One of FEBS charila￿t aims Is 10 5UPPOrt lrfe S￿enceS through Jis events and in 2021 these a¢tiMlie5 were curta4ed. a5 they were in 2020. In Ihese cases. the grants have not been paid were rolled over lo fvnd acbWl￿S in 2022. AS a resu￿ expeTr(htuie tr 2022 is ￿9her due 10 the nwnter of events poswned from 2020 and 2021. Future ￿￿￿￿tments and plans for other *rea$ of FE8S TAorf¢ We now have firm arrangements for a programme DfAnftual Congresses UMII 2024. as these involve s￿b￿antial fts￿3rd pkAnniro. Empendilure on AdVan￿d Coufses up lo 2024 the ¢o*s ol Ihe FEBS EXCel￿NCe Awards e includeij in our budgel5. th regard to future activrties. we ￿ also Corfinuiw to forge cbser bnks wilh relaied European and worl￿1￿￿ organi$alDn$ Ihai co*r MnligutyJ51￿rf3pplng areas of molerJJlar lrfe $C￿ceS le.g. bM)physics, ff*crobiol¢4y. immunology. ¢anorl with l*e aim ol rnaxtrrds￿g the use ol our irnpacls and rescoJrcÉs. Con¢luditt9 FEBS has continued lo operate suceessfulty in promoliiig the aEfvancernenl of research and education f¢y the public benefit in the Sciences of bi¢xhemisiry, molectslai and rdated d15tiplines, and its cur¥enl strategy foi ils lts)*lerm sunnval is progress￿9 smoolhty and accLYding to By mthng wilh 115 re5erve5 FEBS will be in a posiltyl lo prowde Sur￿ io many researchers in year$ 10 come. Appmve¢J by order of Ihe members 01 the board of Twslees a￿$ signed on thwrbehalf by. MOeLaRo Tru51ee Date.. 31 August 2023 Page 16 THE FEDERAnON OF EUROPEAN BfocHEMICAL SOCIETIES IA Company Limiltd by Gu*nn¢e¢l STATEMENT OF TRUSTEES. RESPONS181LITIES FOR ThE YEAR ENDÉO 31 DECEMBER 2022 The Tw51ees (who afe afso the dI￿d0￿ of the Company for the puiw$ of ¢thnp•ny bwl are respon￿ble f eparing the Tr￿steeS. Report and the financial slatement5 in accDrdaTrce with applicabse and Untled Kingdom Ac¢ouniing siandards IUnLted l&ThJdom Genera1yA¢ceptedAcc￿Jnll￿9 Practice). Company law reouires the Trustees lo prepare finanoal statements for each finanaal year. Under company law, Ihe Tiknsiees rnust not approve the financkil slatement5 Un￿$$ they are 5a115fied that they give 8 liue and fair ew of ihe st3te of af13￿$ of the Company and of rts Inccrfning Wes￿JrC2S and ap￿icatiOn of iesources. i*cJu(*ng its income and expenditure. fry that p*iod. In piepaiing these financial statemen15. Ihe Trts51ee5 are reouired lo. se￿￿ wilable accounting FO1￿je5 and Ihen apptyth?rn corF%stenlty." obser¥e the methods and prinoples ol the CharitQ5 SORP IFRS 1021", make judgmenis and accounting estymates Ih818re ￿0$onable and ￿￿￿t. State Whel￿r app&cable UK AccJJnting Slandards (FRS 1021 have ￿en foluwed. sut¥8LI lo any matwial departures disck)sed arrfl explained In the financol swements", prepare the finanErdl slatemenls on the g￿r￿j tontewn basis Un￿5$ it is lnapkKopv￿te to Pfesumt that the Company will contirKR In busine￿. The Tnjslees are responsible for kee￿ng ajequate attounbng Tecord5 that are 5uftiuent 10 Show and explain the Companls transact￿￿5 and disdose wth ieasonat4e acturacy at any lime the finanaal posibon of the Company antl enab￿ Ihem lo eD5ure Ihai Ihe fiTrarKial 5tatemen15 cornpty %4ith the Compan*$ Aa 20Cfj. They are also respOns￿e foT safeguarding the assets of the Company and hence for taking fea&on8è* step5 lor the preVen￿n and dttecbon of fraud other iireguia1i￿S. ApproN*d by order of Ihe Membe￿ of Ihe l)oard of Twustees aTrJ wgned on its behall by.. M Oe La Rosa Trustee O?te.' 31 August 2023 Page 17 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limited by Guaranteel INDEPENDENT AUDITORS. REPORT TO THE MEMBERS OF THE FEDERATION OF EUROPEAN BICCHEMICAL SCCIETIES OPINION We have audrted Ihe financial statements ol The Federats'on of European Biochemical S￿V&￿"es (the chairtable compan￿) for tre year ènded 31 December 2072 wh￿h eomprise the Statement of Financial Activrties, the BaL4n¢e Sheet, the Staternenl of Cash Fk>w5 and the related note5. induding a summary of sNJnificant accounting pOI￿les. The ffinan¢ial reporting fra[r￿S[k that has been applied in their preparation is applicable law and United Kingdom Accounbng Standards. Including Finanual Reporbng Stsndard 102 The Finanaal Rèporting standard applicable in the UK and Rèpublic of Ireland, (Unrt•d ￿"Ag¢JOrn Generally Accepted Accounting Pradicel. In our opinion the financial ststewents.. gNe a true end fair VI￿ ofthe stste ofthe chantablÈ coryanls affairs as at 31 Dècember 2022 and of rts incoming resources and application of resour￿. including rts income and èxptn¢Jiture for the year then Ènded". havè been prop•ty prepared in aecordance with UThted ￿ngdorn Generally Attèptèd Accounting PractKe'. and have bèèn prepared in ac(iJr(lan￿ w*h the requirew*nts of the Conyanies Act 2DC6. BASIS FOR OPINIC Wè eonducted our aut1rt in accofdance with Inlernat￿)naI Stand8rds on Auditing {UKI IISAS IUKII and applicable L8w. Our responsibilittes underth05e standard$ are furlher described in the Audf(or5' respon5ibilrtte$ for the audit ol thè financial statements secbon of our report. We are independent of the chantable company in accordance with Ihè èthi(al requirements that are r*￿vant to our audit of the finanaal stalements in the United Kingdom. Including the Financial Reporting Council'5 Ethical Stsndard. and we have lulfilled our other ethical ponsibilrties In accordance with thesè requirements. We believe that the audr( ev¥Jence we have obtained is Suffirient and approprk3te to provhle a basis for our opinic￿. CONCLUSIONS RELATING TO GOING CONCERN In audrting the financial ststements, we have concluded that the Trustees, use of the going conc•m basi5 of aCC￿nting in the preparnb.on ofthe financial statements is appropriate. B85ed on the wort we Mave performed. we have not Klents"fied any material uncertaint￿S relating to events or conditions that, indNidualty or collecbvely, may cast s¥nificant doubt on the charitable companls abilrty to continue as a going concern for a peiiod ol at least month$ from when the fin¥n¢ial statements are authorised lor issue. Our responsibilrtie5 and the fesponsibdth'es of the Truste¢$ wth resped to 9)iTrJ concern are described in the relevant secbons ofthB reporL Page 18 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES {A C4xwy LI￿¥ted by Gu¥anteel NOEPENDENT AUOITORS. REPORT TO THE MEMBERS OF THE FEDERATION OF EUROPEAN 810CHEMICAL SOCIETIES ICONTINUEDI OTHER INFORMATION The other information comprises the information included in the Annual Report clher than the financial ststeN*nts and Ouf Audrtors. Report theieon The Trustees are resptsnsiblè for the other information contained within the Annual Report. Our opinion on the finanual staterr*nt5 does not cover the other information and, exceptto the extent otheTh¥isè explicitly stated in our ieport, we do not express any fom of assurance conclusion thtreon. Our responsibilty i% to read the other informabon and, in doing 50. cOnS￿eT whether the other informaion is m*erially inconsistent wth thè finan¢ial st*em¢nts or our knowledge obtained in the course of the audrt, or othewse appear5 to be materialty rnisststed. If we identify such material ineonsistèncits or apparnnt material misstatements. we are required to delefrritne whether this gjves rise to a matèrial misstatèmènt in the financial statements thern5elves. If, based on the work we have performed, we conclude that there is a material m1551alerrent of this tsther informat'on. we a￿ reqvired to report that facl We have nothing to report in this regard. OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006 In our opinion. based on the work ￿dertaken in the g)urse oflhe audit the in1￿M01[0n 9Nen in the Twstees. Report for the financial sEar for whth the financial $18lements are prepared is consistent wrth the financk?I ststements. the Trustees. Report has been prepared in actofdanee wth apo*abbe legal requirements. MATTERS ON WHICH WE ARE REQLIIRED TO REPORT BY EXCEPTION In the I￿￿t of our kno¥￿edge ant1 understandin9 of the charrtable company and its eNronment obtained in the cou¥se ol th6 audit. we have not klènth"ffied rrotellal misststements In the Trustees. Repo We have nothing to report in respect of the matters in relation lo whth Companies A¢t 20C6 require5 us to report lo you rf. in our opinion". adequate accounbng records have not been kept or retums adequate for our audrt have not been receNed from branches not wsited by us." or the finaneial staten*nts arè not in agreeTh￿nt with the accounting records and returns.. or certain ¢Jisclosures ol Trust•e$' remuneration specffied by law are not mat1e,' or we have not receNed all the inforrrrats.on and explanations we require for our audrt." or the frustees were not entitled to prepare the financial staterTEnt5 in accordance the small companies regime and tske a¢fvantage of the Small companies. exemptions in praparing the Trusteès. Report and from the requirement to prepar¢ a Strategic Reporl Page 19 THE FEDERATION ()F EUROPEAN BIOCHEMICAL SOCIETIES (A Company Llftwted by Guarantee) INDEPENDENT AUDITORS. REPORT TO THE MEMBERS OF THE FEOERATION OF EUROPEAN BIOCHEMICAL SOCIETIES ICONTINUEDI RESPONSIBILITIES OF TRUSTEES As explained more fully In the Trustees. Responsibilrt*s Statemen( the Trustèes (who are also the directors of the charrtable company for thè puiposes of company are responsible for the preparation of the financial staternents and for bwng sabsfied that they give a true and lair view. and for such internal ￿ntrol a5 the Trustees determine is necessary to enabk the preparatscffi of financial statements that are free fiorn rnaterial misststerrenl, whether due to fraud or error. In prèparing the financial statements. the Trustees are responsible for assessing the chartiable companY5 8blity lo continuè as a going concein. di5¢bsing, as applicable. matters related to going concern and using the going concern basB ol aco)unting Un￿$$ the Tnjstees erthe( ￿end to I￿U￿ale the chantable eompany or to cease opefations, or have no reali5b"c atternative but to do so. AUOITORS. RESPONSIBIUTIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS Our objectNes are to obtain reasonable assurarte about w￿her the financial s18lemenls a5 a whole are tree from material misstatement whethei due to fraud or error, and to issue an Auditors. Report that includes our opinh)n. Reasonable assuraneé is a high ￿Ve1 of assuranc2, but is not a guarantee that an audrt conductèd in accordancé wrth ISA5 {UKI wll afvlays detect a mater*1 misstaten*nt when rt exists. Misstatements can arise frorn fraud or error and are considered material il. indwidualty or in the aggregate. they could reasonably be expe(*ed to influence the econonNc decisbons of useis tak¢n ¢Jn th¢ bast5 Of these [￿anCIal ststements. Irwularrties, including fraud, are instances of non-complianee wrth law5 and regulations. We design procedures In line wrth our responsibil￿e$, outlined above, to detect matefial mi5state￿￿￿ts in respect ol irregularrties. including fraud. The extent to which our procedures arè capable of ¢Jetecling irregulailbes, in¢luding fraud is detailed below. We obtsined an understandin9 ofthe legal #nd regulatory frarr*works through our acoJmul8led knovAedge and eon5iderabgn of se¢tor information that i5 applicable to the charitable cornpany. We determined that the most signficant art directy relevant to speufic asserb'ons in the financial ststements are those related to the finanrAal reporting framework including but not linNted to Unrted Kingdom Generally Accepted Aceounting Prath"ce. the Charf(ies Act 2011. Charits"es SORP. the Companies Act 2006. Data Prtste¢b"on Act 2018 and tax legislats'on. We obtsined an undèt5tsnding of the pKocedures and controLs over the charrta￿ts eompanls operatKJns and disc¢Jssed these those tharged with govemance. No ffotters of fraud were brougm to our attent￿n during that dixussion. During our discussions wth management. they assessed these as being the noimal risks required to be considered by us as audrtors bythe Audrtirbg Stsndards Isuch as management overrNJe and revenue recognition) but confimed that no irregularrtie5 here occurred This was confirmed by our reV￿W of management meetings, audrbng management ovefride throu9h journal testing. and other adjustmènt$ to consider appropnatÈnes5. review of the financial ststements to ensure no unusual and l or Inexplicablè variance5 and general diS￿ss￿lnS with managerTEnt during the course of the audr(. We did not ident any s*3nfficanl business transactions out￿de the nom)al ￿urS¥ C*lthe bu5ines$ operatK)ns. Our senior ststutory audr(oi has assèssèd that the audit team possessed the abilrty and competence to hlentify and reco9nise non-complpnce wrth the relevant law3 and regulations central to the operation of this charitsbk company. We have not ldentff￿d any addrtional laws and regulatsons Yrfhieh are central to the entitys Operat￿n$ and Wh￿ we were not nots"f￿￿ about, during the course of our audit ffi¢ldwork. Page 20 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES {A Company Luhited by Guarahteel INDEPENDENT AUDITORS. REPORT TO THE MEMBERS OF THE FEDERATION OF EUROPEAN BIOCHEMICALSOCIEnES ICONTINUEDI We beI￿ve th* our audrt ￿d$ Capab￿ of deteeb"n9 rrAtèri•l irregularrt4e$, ift¢luding Iraud. and our audit procedures were designed to respond to ri5k5 of matenal misstaterrent in the financial statèments. recognising that the risk of not detecting a matenal misststement due lo fraud is higher than thè risk of not detecting one r?sutting from error, as fraud rr¢y invofve deliberate Concea1n￿nt by, for example. forgery, misrepresenlatigns or through collusion. There are inherent 1imrtat￿)nS rn the audrt procedures prfom*d and the further renw)ve¢J non-compliance with L8w5 and regulat￿n$ Is from the events and transathons reflected in the financial statèmènts, th¢ knss likely to bteomè awar¢ of A further desCript￿n of our responsibilities for the audil of the financial staterr￿ts is located on the Financial Reporting Counal's websrte at by1￿.fr¢.Qr .uklaudrtorsres nsibilibes. This ￿e￿riPtIon forms part of our Auditors, ReporL USE OF OUR REPORT This report is made solely to the charrtablè ct)mpanls rrembers, as a body. in accordance with Chapter 3 of Part 16 of the Coryjanies Act 2006. Our audit work has been undertsken 50 that wè might state tg the charrtable company's members those matter5 are required to state to them in an Auditors, Report and for no other purpose. To the fijllest extent peM￿e￿ by law. we do not accept or assumè responsibilty to anyone other than the charitable corYFany and rts members, as a body, for our audrt work, lor this reporL or lor the opinic￿S we have lom￿d. Mark urra f¢r and on behalf of Hill Wooldrldge & 107 Hindes Road Harrow Middlèsex HA1 1RU A FCCA (Senio¢ ￿ut¢ry Auditor) . Limlted Oata." 31 August 2Q23 Page 21 THE FEDERATION OF EUROPEAA BIOCHEMICAL SOCIETIES (A Company Limited by Guarante•) STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNTI FOR THE YEAR ENDED 310ECEMBER 2022 UnrestrKted funds 2022 Tot¥1 funds 2022 .Total funds 2021 INCOME FROM: Donaltons Charitable actimb.es Investrnenls Other income 6￿60 7,170.000 930,724 56.938 8,044 7,156,235 749,092 12,260 7,170.￿0 930.n4 S6.936 TOTAL INCOMe 8.164,320 8.164,320 7.925,631 EXPENDITURE ON: Raising funds Charitable activrti8S S31,513 6￿50.091 531.513 6.5S8,091 462,734 3.243,527 TOTAL EXPENDITURE 7.089.604 7.089.604 3,7C6,261 NET INCOME BEFORE NET GAINS ON INVESTMENTS N8t11055Vgain on investments 1.074.716 1.074.716 (10.964.737> 110.964.7371 4.219,370 12.241.697 NET MOVEMENT IN FUNOS {9.890.021) {9.890.0211 16.461.067 RECONCILIATION OF FUNDS: Totsl funds brou9ht fornvard Nel movement in funds 99,178,699 99.178.699 19.890,021) (9I90.021} 2.717,832 18.461.067 TOTAL FUNDS CARRIED FORWARD 89288.678 89,288,878 99,178,699 The Statement of Financial Aetpl￿.e5 rn¢tyJdes all gain5 and losses rewgntsed in the year. The notes on pages 25 to 44 foffli part olthe5e financral staterrentS. Page22 TrIE FEDERATION OF EURopeAM ￿0¢￿EmICAL SOCIETIES IA Company Limited by Guarante•l REGISTEREO NUMBER: 08239097 8ALANCE SHEET AS AT 31 0ECEM8ER 2022 2022 Nole FIXED ASSETS Tangible asse15 Investmenls Scrtial inveslments 12 13 63.507 83.177.926 76.368 92.034,956 72.129 14 83.241.433 92.183.453 CURRENT ASSETS Oeblo Cash at bank and in hand 15 358.895 6,332.321 436,652 7,130,070 6.691.216 7,$66,722 Crethiors". amovnts falling tlue one year 16 1643,9711 1571,4761 NeT CURRENT ASSETS 6.047.245 6.995.246 TOTAL NEW ASSETS B9.288,678 99.178,699 CHARITY FUNOS Unieslri£ted lunds 18 89.288.678 99,178.699 TOTAL FUNDS 89.288.678 99,178.699 The Trustees aCkn0￿e¢sae their resronsibilthes for ￿mth'n9 With the requirement$ of the Act wlh respect lo accounbng records and preparntw of financts￿ statements. The financial statements have been prepar*J in accordance with thÈ prw$ions appFK•ble io entrties subject tts the Small c(vnpanies regime. The finarK5al statements were approved and authorised lor issue by the Truslees and syned their behalf by: F. Mlehelanptli Trustee Date." 31 August 2023 The notes on pages 25 to 44 fom part of these finar￿￿1 statements. Page 23 THE FEOERATION OF EUROPEAN BIOCHEMICAL SOCIETIES ' IA Company Limited by Gy•r•nteel STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER X*22 2022 2021 Note CASH FLOWS FROM OPERATING AcT￿￿lEs Net cash us•tl in operating aetivitses 20 307.105 3,725.785 CASH FLOWS FROM INVESTJNG ACTWMES Omdends. Interests and rents from investments Purchase of social investnwnt RepayThent of s￿181 Investry￿￿t Proceeds from sale of investh*nts Purchase of invéstmènts 930,724 T49,0￿2 172,1291 72,129 31,539,222 60,940,844 133.646.9291 163,487,550) NET CASH USED IN INVESTING ACTIVITIES 11.104,8541 11,849,743) CHANGE IN CASH AND CASH EQUIVALENTS IN THE YEAR 1797,7491 1,876,042 Cash and cash equNalents at the beginning ofthe )tar 7.130.070 5,254.028 CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR 21 6.332.321 7,130,070 Thè notes on pages 25 to 44 fomi part ofthese financial statem•nts Page 24 THE FEDERATION OF EUROPEAN BIOCHEMICAL SCtIETIES IA Conwany Limiled by Guarant••l NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 ACCOUNTING POLICIES 1.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS The finanual statements have been prepared in accordan¢e vthh the Charibes SORP IFRS 1021- Attounting and Reporbng by Charth"ts." Statement of Recommended Prèetsee applicable to chaTitI'es preparing their accounts in accordance ￿th the Finanual Rerxjrting Standard applicable in the UK and Republi¢ gf Irdand IFRS 1021 leffedNe 1 January 20191. the Financial Reporting Standard applicable in the UK and Republ￿ of Ireland IFRS 1021 and the Charities Act 2011 arnd the Companies Act 2￿. Assets and Imbilrties a￿ inrtialty recognised at historical ¢951 or transaction value unles5 clherwise ststed in the ￿levant accounb.ng Foly. The Federation of European Biochewical Sccieties Ir￿ts the definition of a wbli¢ benerrt enlty a5 defined by FRS 102. There were no swJnificant estimates or judgÈments made by man89èment in preparing these finanual statements. The fvnth.onal and prèsentational ￿llencY is the Euro. 1.2 GOING CThNCERN The Trustees have consmjered the Companys forecasts and project￿nS. After making erquires, the Trustees have concluded that there is a reasonable expectation that the Company has adequate resources to conth.nue in operational existence lor the foreseeable future. Therefore, these accounts have been prepared on the going concem basis. There are no material Uncertaint￿ in ￿lab.On to ts￿ng concem. 13 INCOME AJI income is ￿CogniSed Or￿e the Company has entit￿ment to thè ineomt, it is probablè Ihat thè income wll be received and the arrw)unt of ineomè receNable ean be measured reliab￿. Income from rorotties is rewnised in kne %wth the period to which it rel*es. In¢grre from grants and donat￿n$ are recognvd the Company has been nots"fi8d in Wr￿ng of both the amount and 5etU•ment date. In the event that a grant or donatKJn is sybiecl to condrtions that require a level ol perfoimance before the Company is entrtsed to the lunds, the Inco￿￿ Is delerred and not recogni5e*J unbl those Condit￿nS are ftjlly me( or the fulhllment ol those condrtions is whdly vithin thè control ol th• Company and rt is probable that those conditsons wll be lulfilled in the reporting peiiod. Investmènt in¢ome 15 ￿COgnIsed in the period in which the Company ￿coMeS $nt￿e￿ lo the incoTr*. Interest on funds held on deposrt is included when r￿eNable and the amount can be measLsrg0 reliably by Ihe Company. this is nommlly upon nobficatron of the interest pahd or payable by the Bank. other income is reeogni5ed in the Perh￿ in wthich it is receivable and to the exient the goods have been provided or on coMpl￿"0n ol the service. Page 25 THE FEDERATION OF EUROPEPJ4 810CHEMICAL SIXIETIES IA Company Limit•d ty Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER XJ22 ACCOUNTING POUCIES ICONnNUED) 1A EXPENDITURE Expenditure is Tecognised oncè theie ts a legal oi eonstructivè ob19at￿Tr to transfer economic b?nefit to a third paty. rt 15 probable that a transfer of economic benefit5 wll ￿ r•quir•d In settlement and the armunt ofthe obh3a1￿Th can be n*asured rella￿y. ExpÈndrture on rai*ng lunds indude5 all èxpèndrture incurred by the Company to ratse funds lor its charitable purposes and Includes costs of all fundratsing actsvit￿S events and nonN OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES JJ22 2021 Net 18xpendrtUrè￿lne•ft￿ for thè year (as per Staterrent of Financial Acbvrties) 19,8W.021} 16,461.C67 ADJUSTMENTS FOR: Depreciatr'on charges Lossesllgainsl on investments ONidends. inttrrests and rents frryn ￿estr￿ntS Decrease in debtors Increase in credr(ors 12,861 14,885 10,964.737 112.241.697 1930.7241 1749,0921 77.7S7 118,242 71495 122,380 NET ¢￿$H (USED INVPROVIDED BY OPERATING ACTIVITIES 307,105 3,725,785 21. ANALYSIS OF CASH AND CASH EQUIVALENTS 2022 2021 Cash mi hand 8.332.321 7, 130,070 TOTAL CASH CL8H EQUIVALENTS 6,332,321 7,130.070 Page 43 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limited by Gu•ranteel NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 ANALYSIS OF CHANGES IN NET OE8T At31 Dtetmber 2022 January 2022 cash Ilows Cash at bank and in hand 7.130,070 1797.7491 6,332.321 7.130.070 1797.7491 6.332.321 23. OPERATING LEASE COMMITMENTS At 31 December 2022 the Company had commthènts tts make luturè minimum lease payments undèr n0n-c8nce1￿b1e operating ￿aSeS as follo￿.. 2022 2021 Not later than 1 year Later ihan l year and not later than 5 year5 S5,969 13.992 58,967 73,709 69.961 132.676 24. RELATEO PARTY TRANSACTIONS The Corrpany has not entered into any related paty transaction tluring the year. nor a￿ Ihere any outstsnding baknces owng beN¥een rÈL4ted Pa￿"•$ and the Company at 31 December 2022. Page 44 APPENDIX 1 Constituent Socie Armth• Address Association of Armenian Biochemists IAABI H. Buniatin Inst. of Biochemistry, National Academy of Sciences. Sli Paruyf Sevak Str. Yerevan 375D14 Republic of Armenia www.aab.sci.am Osterreichische Gesellschaft fvr Molekulare Biowissenschaften und Biotechnologie IOGM8TI Ma￿0X. VBC. Helmut-Qualtingerfjasse 2. Stiege 02, EG L.01. 1030 Wien Austria www.oe mbt.at BefaNs- IAssociorel The Belarusian Soctety of Biochemists and Molecular 8iolo@ists18S8M81, Institute of Biochemistry of BiologicolW Acttve Compounds, Nattonal Arademy of Scienw, 50 Lenin Komosornol 8oulevard, 230030 Grodno, Belaws. Société 8èlge de B1￿hlmIe et de Biologie Moleculaire IBMBI, Nanobody Lab, Dept. of Biochemistry, Ghent Univeisity. Altert Baertsoenkaai 3 gX(J Ghent 8el8ium www.bioth mist .be Èdglum 805nla and Her2e8oMna Association of Biochemists and Molecular Biologists in Bosnia and Herzegovina IABMB in 8&HI Faculty of Medicine. University of Sarajevo, tekalula ￿. 71(U) Sarajevo, Bosnia and Herze8offlna www.ubmbubih.net 8ulgarian Biwhemical. Biophysical and Molecular Biology Sooety IBBMBSI, Institute of Btophysic5 and 8iomedical En8ineerin& Bulgarian Academy of Sciences. Acad. G. 8onchev st.bl 21. Sofia 1113. 8ulgaria www.old.uslFb or sections.htm Croatian Society of Biochemistry and Molecular Biology IHDBMBI. Ksaverska cests 2. HR-ICKJOO Zagreb Croatia www.hdbmb.hr OLO<-Sooecy of &0108ical Sciences in Cyprus l¥io(-SBSCyl. Department of Biological Scierices, Univer51ty of Cypius. l University Avenue. Aglandjia 2109. Nicosia, Cyprus htt Ciech &iciety lor &'ochemistry and Molecular Biology ItSBM81. Kladen5ka 48, CZ-16 000 Plague 6 Czech Republic www.c5bmb.ci Danish Biochemical Society (Dansk Biokemsk Foreningl. Unit of Cell Stress and SurvNal. Center for Autopha8y, Recycling and Disease. Danish Cancer ScKiety Research Center. Strarbdboulevarden 49, OK 21CM) Copenha en O. Denmark www.knoketri.o¥ en Estonian 8iochemical S(Kiety IEBSI. Tallinn Uruversity of TeCh￿l08v. Ehitajate tee 5. 19086 Tallinn, Estonia www.biokeemiaselts.ee Societas Biochimica. Biophysica et Microbio108ica FennIae(8￿bio Society). University of Helsinki, Haartmaninkatu 8, He15inki Finland www.biobio.or Société Francaise de 8iochimie et Biologie Moléculaire ISFBeMI. IBMC, 15 Rue René Descartes. 67084 Strasbour Cedex, France www.slbbm_fr Assotiation of Georgian Bio¢heffli5ts IAGBI. Institute of Chemical 8iotyy, Ilia State VnNersity. 315 K.Cholokashvili Av.. Tbilisi 0162. Geor Gesellschaft fur Biochemie und MolekularbiolL%ie G8M e.V. IGBMI. Morfelder Landstr. 125 0-60598 Frankfurt/Main, Germany www. bm￿nI1ne.de Hellenic Society of Biochemistry and Molecular IHSBM8111 Soufliou Stfeet. Athens IIS 27 Greece www.eebmb. Hun8arian Biochemical Society Imagyar Biokémiai Egyesulei- MBKEI. Institute of Enzymology. Research Center for Natural Sciences, Hungarian Academy of kiences. Magyar tudosok korutja 2. H-1117 Budapest, Hungary www.mbke Israel Society lor Biochemistry and Molecular Biology IISBMBI. Dept. of Biological Chemistry, The Alexander Silberman Institute of Lrfe Science. The Hebrew UnNersity of Jèrusalem. Givat Rèrn Campus, Jerusalem 91904, Israel www.weizmann.ac i isbmb Bul8arla Croatla C2ech Aèpublk Denrnark Estonla Flnland France Georw Gennany Hu￿ry l$rael Societa Italiana di 8iochimica e Biolo8ia Molecolare ISIBI. Dip. to di Scienze Biochimie 'A. Rossi Fanelli.. Sapienza Universita di Roma. P. le Aldo Moro S, CK)185 Roma. Ita￿ www.biochimica.i Latvian Biochemical Society ILa851. Latvian Biomedical Research and Study Centre, Ratsupites Street I, LV 1067 Riga. Latvia Lithuanian Biochemical Society ILBDI. Sauletekio al_ 7. LT-10223 Vilnius. Lithuania www.biochemist .11 iat¥4a Lbthuanla Moldova (Associotej Moldovan Society of 6iochemistry and Molecular Biolo￿ IMSBMBI. Institute of Genetics. Phy5io108y and Protection of Plants. Academy of Sciences of Moldova, 20 Padurii Str.. Chisinau. 2002-MO Moldova Moroccan Society of Biochemisiry and Molecular Biology1SMB8MI, Ha55an 11 University of Casablanca, Laboratory of Sciences. Faculty of scie￿es and Techniques. 8.P 146 Quartier Yasmina, Mohammedta, Morocco The Netherlands Society for 8icKhemistry and Moleculaf Biology INVBMBI. NMR Group. Dept. of Chernistry, Utrecht LJnlver￿ty. Padualaan 12. 3584 CH Utrecht. The Netherlands www.kncv nl nvbmb Norwegian 8iochemical Society INBSI. NTNU, Fakultet for medisin og helsewtenskap. 7491 Trondheiffl. Norway www.biok"emisk.com Polish Biochemital Society IPT Biochl. Nencki Institute of Experimental Biology, 3 Pasteur str. 02-093 Warsaw Poland www. tbioch.edts. Portuguese Biochemistry Society ISP81. Faculty of Pharmacy. University of Lisbon. Av. Prof. Gama Pinto. 1649-003 Lisboa, Portu al www.s Romanian Society of Biochemistry and Molecular Bk)logy IRS8hABI. Institute of Biochemistry, Splaiul Independentei 296, sect. 6, 06Th)31 Bucharest. Romania www.srbbm.biochim.ro National Commitiee of 8iochemist5 anij Moleculaf Biologists INCBMBI Shemyakin-ovchinnikov Institute of Bioorgansc Chetni5try. RAS. Ul. Miklukh¢FN4aklaya, 16110. 117997 Moscow. Russia www.rusbiochem.or Serbian 8iochemical Society ISBSI, Depanment of 8iochemisiry. Faculty of Chemistry. University of Bel rade. Studentski tr 16. IIWO Bel rade Serbia www.bds.or rs en home.html Slovak Society for Biochemistry and Molecular 8iology ISS8M81, Dept. of Mo)lecular Biolo&w, Faculty of Science. Chades Llniversity In Bratilava, Ilkowcova 6, 842 15 Bratislava Slovak Republic www.ssbmb.sk Slovenian Biochemical Society ISBDI. Universtty of Ljubljana. Faculty of Medicine, Vrazov trg 2, Sl- I(KK) L ublj3na. Slovenia www.5txl.51 Sociedad Espafiola de Bioquimica y BiologTrca Molecular ISEBBMI. CIKSIC. clRamiro de Maetzu, 9 E-28(MD Madrid, S ain www.5ebbm es Svenska Kemisamfundet (The Swedish CheM￿al Society.. SFB8MI, Svenska KemisamfvndeL Nafingslwets hus. Storeatan 19, SE-114 51 Stockholm. Sweden htt kemisamfundet.se sektioner biokemi-biof sik-oth-Tnolek larbiolo Life Sciences Switzerland ILS21. Swiss Society foi Moleculor and Cellular Biosciences. MCB section of L52. Institute of Cell Biolo Universrty of Bern. Switzerland www.152.ch TheTunisian Association of Biological Science5 IAT5B- A550Clation funisienne des Sciences 8iologiques-l Dep Biolo8ie- INSAT. Université de Carthage. 8P 676- Centre Urbain Nord, ID80 Tunis cedex. Tuni5ie Www.ats￿b4o.0r Turkish 8iochemical Society (TBSI, Ege University. Faculty of Medicine. Oept. of Biochemistry. 12mir, Turkey www.turkb" okim rne Ukrainian 8iochemical Society IUBSI, Palladin Institute of 8iochernistry. 9 Leoniovicha SL 01601 Kiev-30 Ukraine www biochemist .or .u Index. en The 8iochemical Society, l Naoroji Si. London. WCIX OGB. UK www.biochemisi M￿1￿£0 {Associotel Netherlands Norway Pojand Portwl manl* Serbla Slovakja ovenla Spaln Sweden SwStterland Tuni51a {As50CiOte} Torkl Uknlne united Kln om .or FEBS had 39 Constituent Soc*ties in 2022, comprising 35 Member Societies and 4 Associate Member Societies. APPENDIX 2 ."i. Sulxrl 120 C l A$souati￿ clArNtnian BAfftmi5ts 30. 2 Av$rr￿fiAssQC￿t￿ffj cfmdecular LiffeSc*rttsaftd ￿￿et￿loGMBT) 626 156.50 3 Sociéré Bellede ts￿1￿￿et de Biolcye WwJtsire 125.( 4 ABM8 in 805nia and 1*rzegL￿oa 10) c 25.0) 5 bulyrian S0(ietyfw Bmxhemisrry. m￿ecU￿ èK4oy 6 &oati* sor￿¢1 BK)theffM5tryand Mc4ecu* Bvj 514 C j28.gj 7 Sooetyof 8iob28iC31 S¢erKe56ThCvkYus 120 8 Czeth Soaetyftr BK) 620 s.tx) 9 so)etyf￿ g*xhemtsbryand 8b)k• 95.Dl IQ EstorMaTh Stixhernlc* Souety 27.50 11 Suc￿a5 BA)CheM￿a. B￿l[￿￿'(ae¢ Fenrriae 515 128.75 12 &xété F¢an(￿de ewxhin* etde 8￿￿e*Ar￿*￿￿e ISFBBMI 325.co 13 A$s￿all0￿ ofGeu8ilh) &￿ther￿St5 14 Gesellxhèft fur und e.V. 20.75 1870 717.$0 15 Hel*rM¢5ocietyof ￿￿￿e￿Astryand Mdecul¥ &okfflf IS Hungari￿ 8kithemK* knety 17 15rad Soaetyfot BiothEmLttryandMdeO￿Jr Blob 200. 41 C 10.25 18 rt31ian Soaetyof B*?themi5tryand B i.(ts) 250.( 19 L3tw3n BI0thernK￿ Sotiety 20 tilhuan1￿ eK)¢hemK4 Soc*ty 265 C Zl NederlèndseVerenIgtngvr￿ Trthyttdaire B￿"¢ I,C67 C 266.75 22 P+arw￿laTr Stiuety 75.co 23 Pof15h èty?chemd 1.014 253.so 24 P¢nugue5e 810chw￿¥l 350 87.50 25 ￿letate¥ Rom3na de B￿Mies1 I￿e¢uL￿a 26 Serban B￿CheMic& Sottty 45. 27 Ycwak Sooetyfw 9Kxhernwry￿d MokniLv &0 55.f 28 SIr*¥eni￿ a￿err¥Ol &x5E 220 5S.C 29 EspaTrYède Bwu¥nthy BK•*ica Mdetul¥ 2.911 C 727.75 30 Swedishsooety 8thern￿ry. bwtrrysK5￿)d Mdetul¥ 426 106.9) 31 Ule SCIe￿e$SwIt1Iand ILS21 947 236.75 32 Turknsh &"¢th￿Kè1￿ety LSO.ts) 33 &lKhern￿lS0tsety 6,137 C L534.25 34 Ukiaihiafi 8￿1th¢m￿ S(K*ty 170.CY) Tolal 25,836 É 6,459.LXJ OCIATE MEMBERS . *4..- Moldwan 5ooetyot B￿Cheft￿$tryano Mde¢ukr 8h?108y IMSOMOI Morto¢HlCAL DlSfRIBulloN OFTHE MEMBERS APPENDIX 3 jan￿ry L 2022- Deeefflber31, 2022 twmer4ts1 pogyonfor {r*ldecii￿ tostart l.L2023 EJ TreagJrw Adn8Trea5urer vadt4 Paees IEx-omdoJ Lknited KJr*dom 010121 010118 J0916 311223 311220 311217 Cuch ￿ubl￿ 010120 010117 010115 .3112 22 311219 311216 FINP*IC£COMMirrEE F￿k MIchela￿elL tha tknfted Wn8dorn cmllne12020) jerU￿￿n {20171 Munlth12016) 010121 010118 C8￿16 311223 311220 311217 A¢UngTreagJrer Frantesco Bonoky ltr)e120201 010121 311224 Jod Sussrnan Kjakow (20191 0120 311223 vadov Pale5 IExQfflckn} etsry Gener Czeth Republk Krakow120191 Parfs120141 Pad$120141 010120 010117 010115 "3112 22 311219 311216 Johwnes ￿thTher IErt)frlo} thalr, PuNlcatfjcffis C£¥nrnlttoe Germary online120201 010121 311223 Laszlo Fé￿)S IC¢wtsd) Huwry 010121 .3112 22 PUBUfATIONS COMMfryEE Jthannes Buthner. Chalr Ge￿￿Th¥ (mllne {20201 010121 311223 Marc 8aumann Fknl¥ L￿1￿e(2020I 010121 311224 CongJelDGuwrl Spa {20181 010119 .3112 22 Jthannes Herrrnann Ilne12021) 010122 311225 Mardn Malka Pt4and Ilne12021} 010122 311225 Mosialos up120181 010119 .3112 22 Frar* Mlthelangell fEx-Ollth) (mlkne120201 Jwusalern12017) Munlth120161 Krakow12019) Parf512014} Parts12014) oisn 010118 (8C816 311223 311220 311217 £tln8Treasurff Vadav PatÈs ILTrfftiol Clath Iwublk 010120 010117 010115 .3112 22 311219 311216 saEKEfvNDSoCI￿y CC*AMrrrEE Errffianoull Fra¢￿11$, Kraku#l2019) Murlch120161 online12020) 01￿20 010117 .3112 22 311219 MauroTtyti 010121 311224 Mdlts Vldak(p*i IIne12￿1) Ql(ll22 311225 Enrlque 14lnbwe2 onlkne120201 010121 311224 Raffaele Porta Icwted) C(￿oPted{2ffllj jerusa￿ (20171 0122 oioi 311222 311221 tsabel Varel*Nleto ICowtEd) 010121 010117 Munlth120161 311220 Frank Mithelanudi (ExQfrknJ United KSn8dom online120201 Jerusath12017) Munkth12016) 010121 010118 C8C816 311223 311220 311217 Vad•4 Pat• fE¥QffthJ Qeth P•U￿1C Kr•kow12Q191 Parls120141 P¥is12014) 010120 010117 01￿ .3112 22 311219 311216 Miguel la Rosa C Couhsdlor fEx-OJAkknJ linel20201 jeru511￿(2017) Parts12014) 010121 010118 oioiis .3112 22 311220 311217 WORKING GROUP ON CAREERS OFycWI￿ XIENTISTS Irene Dtaz-Mc(eno. Cha 5patn Ihe120x)I Jerus8kn12017) 010121 01￿ 311223 311220 nna J4gu4ak (Co•tedJ Pdand 01￿21 .3112 22 Vlasumll Kulda (Co•J C2eth ￿pUblIC 311222 lerka [￿mIe ICtr(pted} 010122 311223 Frank Mlchdan8ell (Ex4)TtknJ Treasurer ActlnB Treasur United Kr¥d OnN￿l2020) Jeru5aem12017) Munkh {2016} 010121 010118 09(816 311223 311220 311217 vadav Patss IExofflcknl Seuetary Genera} Qeth P4ubllc *12019) P*$ (2014} Pwis12014) 0120 010117 oioi .3112 22 311219 311216 WORKING GROUPON lTr[￿GRATION (WGII Jerka (halr Krakuw 1x1191 Munith120161 FWI20￿) oi(n20 010117 "3112 22 311219 Berfec srwla 010119 .3112 22 Tatiana 80rt5v4a r*ne FW {2￿8) 010119 .3112 22 Frnnk Mithelanudi fE¥Qfv)I Unlted Kn8dom FE85Ath4nc¢d LÈctur*Ctyw5etsieic4r SuifatÈS and Inrerfa¢es"Fry￿s èt 11-17 I¥l4Jw￿lQ22 I9.24￿￿ 2022 FE85Pr4c￿I cours•"Mkrospecfftc&xi.' FuDclkn4llMa*￿O18￿￿1Cal 5Trsfgrn5" Jssopt Zm2 Drlr•r•D￿1- 2¥25Al•tth 2022 FEU5AthntedLettvreCourse￿ 1>1S5vpt7022 Ex￿o￿nitheh￿fft l[•Dxrlptornlc5•nd wclrcnielty p￿I.•A+thL￿S IlhlEn IL-L6Sept2022 erthDr¢•rye15 fw4ntt.•¢wie knttr¥wtity* 36s*ot- iOu2022 14511n1ntèva￿n-pr0E4fftg￿￿r&￿￿5w1th ¢*tV¢n5.photsi5. r¢utron&ird miy￿¢￿1r p￿1. Nissen >I5￿Y￿2 TtytriYTF 129